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ABSTRACT 
Background/Objectives: Children born to mothers with opioid use disorder often show 
withdrawal effects characterized by increased stress, hyperirritability, tremors, tachycardia, 
sleep deprivation, and gastrointestinal discomfort, commonly known as “neonatal opioid 
withdrawal syndrome” (NOWS). Studies have shown that the effect of NOWS can lead to 
several health-related disorders later in life leading to increased health care utilization. 
However, detailed study of post-discharge health care utilization, specifically focusing on 
encounters with the health care system is currently lacking in the literature. Our objective 
was to evaluate health care utilization in infants who were diagnosed with NOWS during 
a one-year follow-up period after their discharge from the hospital. Secondly, we wanted 
to assess the relationship between NOWS related severity measures and post-discharge 
health care utilization during a one-year follow-up period. 
Methods: Health Facts® data, collected from over 800 contributing CERNER hospitals 
across the United States, was used to identify infants who were diagnosed with NOWS. 
Health care utilization during a follow-up period of 365 days after the index period 
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(discharge date) was evaluated. As comparators, two groups were utilized: late preterm 
(gestational age: 33 weeks up to 36 6/7 weeks) and uncomplicated birth infants. Outcomes 
measured were rehospitalization, emergency department visits and outpatient visits. We 
used logistic regression model to assess the impact of NOWS on health care utilization 
after discharge. Poisson and Zero-inflated Poisson regression were used to quantify the 
incidence rates of the health care utilization event. Finally, Cox proportional-hazards 
regression was used to estimate time to first event related to health care utilization after 
discharge from the hospital.  
Results: We identified our study cohort as infants who had birth related discharges between 
the period of January 1, 2011, and October 31, 2016 which included 3,526 infants with 
NOWS, 24,474 infants who had late preterm birth, and 88,452 infants who had 
uncomplicated births (representing a 25% sample of the births recorded). Mirroring the 
opioid epidemic in the U.S. there was an increasing trend in the incidence rate of NOWS. 
Infants with NOWS had significantly longer length of stay (14.9 days vs. 2.1 days, 
p<0.001), and higher cost (Median: $24,944 vs. $3,129, p<0.001) compared to 
uncomplicated birth group. Infants diagnosed with NOWS had significantly higher odds of 
one-year rehospitalization (Adjusted odds ratio: 1.7, 95% C.I.: 1.3-2.2) and 30-day 
rehospitalization (Adjusted odds ratio: 1.9, 95% C.I.: 1.3-2.6) compared to uncomplicated 
birth infants. There was no statistical difference in the risk of emergency department visits 
in the NOWS group compared to uncomplicated birth group after adjustment for 
confounders. Infants in the NOWS group had higher odds of any 30-day composite visit 
(emergency department visit or rehospitalization) compared to the uncomplicated birth 
group (Adjusted odds ratio: 1.4, 95% C.I.: 1.2-1.6). The results from logistic regression 
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models closely aligned with the findings from the Poisson, Zero-inflated Poisson, and Cox 
proportional-hazards regression models. Infants with NOWS had similar rates of post-
discharge healthcare utilization when compared to late preterm infants. In examining the 
impact of NOWS severity measures on post-discharge health care utilization, we found 
that some of the measures, such as pharmacological management of NOWS, length of stay, 
receiving medications (e.g., benzodiazepines), and presence of respiratory conditions were 
associated with higher probability of post-discharge health care utilization. While the 
results from logistic regression models were inconsistent, results from principal component 
analysis, which combined NOWS severity measures, showed that NOWS severity was 
associated with post-discharge health care utilization. 
Conclusions/Implications: Our study shows that the higher rates of health care utilization 
of infants who were diagnosed with NOWS is not just limited to a period of hospitalization 
for NOWS treatment but can also manifest for an extended period of time post-discharge. 
Hospital readmissions and emergency department visits could lead to additional physical, 
mental, and financial stress to the families of the affected infants. Furthermore, they signal 
presence of an underlying medical condition that could lead to poor health and even infant 
mortality. The findings of our study suggest that closer follow-up and management of 
infants may be necessary. Additional support to the infant-maternal dyad may help in 
improving health outcomes in these infants in the early years of their lives.  
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CHAPTER 1: INTRODUCTION 
1.1 Opioid use in pregnancy 
Opioid use among women of reproductive age has been increasing steadily over the 
past decade. At least a third of women between the ages of 15-44 years filled a prescription 
for opioid as an outpatient each year between the years 2008 to 2012.1 Reflecting the 
increase in the use of opioids among women of reproductive age, there has been a 
noteworthy increase in opioid use during pregnancy. A report on Medicaid patients stated 
that approximately 21.6% of pregnant women on Medicaid had filled a prescription for 
opioids.2 The rates had gradually increased from 18.5% in 2000 to 22.8% in 2007.2 In 
addition, 2.5% of the pregnant women on Medicaid had received prescription opioids for 
more than 30 days signifying prolonged exposure to opioids.2 In commercially insured 
pregnant women, the prevalence of opioid prescription varied from 6 to 26%.3 Studies 
conclude that the rate of prescription opioid use in pregnant women has grown two-folds 
in the last two decades.1-5  
Increase in prescription opioid use has led to a surge in the non-medical use of 
opioids as well as the use of illicit opioids (e.g., heroin) during pregnancy. As the supply 
of prescription opioids is limited by physicians or as cost becomes a barrier, there is 
invariably a shift towards cheaper illicit opioids which is facilitated by the ease of 
availability.6 The increasing trend in licit and illicit opioid use in women of reproductive 
age has resulted in a sharp increase in pregnant women who required treatment for opioid 
abuse. In 1992, approximately 2% of the pregnant women admitted to a substance abuse 
treatment program reported that opioid was the primary substance that they abused; the 
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proportion increased to approximately 19% in 2012.7 Over two-thirds of pregnant women 
in a substance abuse treatment programs have a history of heroin use suggesting that origins 
of substance use disorder stem from both illicit drugs and misuse of prescription 
medications.8   
1.2 Opioid use disorder in pregnancy 
Opioids are any substances, natural or synthetic, which bind to the opioid receptors 
and modulate the pain, and other neurosensory activities of the body.9 Prolonged use of 
opioids causes an imbalance in the activity of these receptors resulting in the patients to 
show the symptoms of opioid use disorder (OUD). OUD is characterized by craving, 
tolerance, impulsive, and continued use of opioids regardless of the adverse effects on the 
individual’s health.10 As with any disorder, OUD is considered a manageable condition 
that can be treated through medical and behavioral therapy. Medication Assisted Treatment 
(MAT) has been the cornerstone of treatment of OUD.11 The treatment focuses on the 
substitution of illicit opioids by long-acting opioids that addresses the cravings of the 
individual while preventing adverse events that are associated with illicit opioids. OUD is 
treated with a drug that is either a full agonist (methadone) or a partial agonist 
(buprenorphine) of the opioid receptors. Administration of MAT is ideally a part of a broad 
treatment program that consists of addiction counseling, family therapy, and other social 
services.12,13 It is important to note that there are only a limited number of providers in the 
United States that provide both substance abuse treatment and prenatal care.14,15 While 
measures are being undertaken to expand the access to these services in pregnant women 
with OUD, substantial gaps exist in the perinatal and postnatal care of pregnant women 
with OUD.16 
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1.3 Outcomes associated with opioid use in pregnancy 
1.3.1 Neonatal outcomes 
Use of illicit opioids, such as heroin, is associated with increased risk of prematurity 
and intrauterine growth restriction.17,18 Compared to infants born to a mother on 
methadone, infants born to mother who used heroin had lower weight, length, and head 
circumference at birth.19,20 Additionally, evidence suggests that opioid use may be 
associated with birth defects such as congenital heart defects, neural tube defects, and 
clubfoot. However, these conclusions have been derived primarily from case-control 
studies and not all studies were adjusted for prenatal environment.21 A study that analyzed 
the outcomes of prescription opioid used during pregnancy showed greater odds of preterm 
labor, premature delivery, fetal growth disorders, longer hospital stays, and maternal-fetal 
mortality compared to no opioid use.22 Adverse neonatal outcomes associated with in-utero 
exposure to opioids can substantially increase the risk of adverse health outcomes later in 
the life of the infant. 
1.3.2 Neonatal opioid withdrawal syndrome 
More than half of the infants born to pregnant women with OUD develop 
withdrawal symptoms such as increased stress, hyperirritability, tremors, tachycardia, 
sleep deprivation, and gastrointestinal discomfort, which are collectively known as 
neonatal opioid withdrawal syndrome (NOWS), formerly known as neonatal abstinence 
syndrome (NAS).23,24 Reflecting the steady growth in OUD during pregnancy, there has 
been a substantial increase in the incidence of NOWS and other opioid-related adverse 
events.21 These infants require considerable amount of pharmacologic and non-
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pharmacologic treatments, and have prolonged hospital stays after birth leading to a 
considerable economic burden to the health system.25 
1.4 Health care utilization in infants with NOWS 
Infants born with NOWS have prolonged hospital stay and higher health care 
utilization during their hospitalization.25 Strategies, such as standardizing treatment 
protocols, management in outpatient settings, or use of adjunctive therapies for treatment 
of NOWS, have been evaluated to minimize the cost related to management of NOWS.26-
29 These studies aim to decrease the exposure to opioids during withdrawal and/or to 
decrease the length of stay (LOS) in the hospital and effectively reducing the cost of 
managing NOWS.30 However, there is very little consensus on the approaches to treatment 
in NOWS31-33 and its impact on long-term health-care utilization. Furthermore, most 
published research on NOWS is concentrated on the management of withdrawal effects 
and reducing LOS. Studies that evaluate long-term effects in-utero exposure to opioids and 
resultant health care utilization have been overlooked. A report evaluating health care 
utilization in a cohort of 499 infants who were diagnosed with NOWS during the first year 
of their life reported that 15% of the cohort required hospital readmissions and 22% of 
those who were readmitted required further readmissions.34 Another study showed that 
children who had been diagnosed with NOWS/NAS had increased readmission rates in the 
first five years of life compared to controls.35 Infants with NOWS who are discharged after 
less than 7 days of hospital stay have higher rates of hospital readmission compared to 
those who were discharged after 7 days.36 Additionally, infants could also be prescribed 
barbiturates to alleviate their NOWS symptoms.37 However, the safety and efficacy of 
prolonged exposure to barbiturates in the newborn period is not well characterized.38-40 
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While the treatment with opioids (with morphine or methadone) or treatment with 
phenobarbital is effective for the management of the symptom of NOWS, the infants 
require a gradual decrease in the medication dosing until it can be safely discontinued, 
resulting in longer hospital stays compared to infants who did not receive these 
medications. The management of NOWS with these medications early in the life of the 
infant, combined with the effect of in-utero exposure to opioids may lead to poor health 
outcomes later in life. The rising concerns regarding NOWS in relation to the opioid 
epidemic in the U.S. warrants a critical evaluation of its long-term consequences. 
Understanding the various treatment modalities in response to the severity of NOWS and 
the outcomes associated with these treatments can significantly contribute to improving the 
health outcomes and lowering the economic burden of the condition. 
1.5 Study objectives 
The overall goal of this study was to characterize and quantify post-discharge health 
care utilization in infants with NOWS compared to controls during a one-year follow-up 
period. The study utilized two control groups: a primary control group that included infants 
with uncomplicated births and a second control group that included late preterm births 
(gestational age: 33 weeks to 36 6/7 weeks). Secondary controls served as close 
comparators to the NOWS group as the condition overall is considered self-limiting, 
however, late preterm infants are susceptible to poor health and increased health care 
utilization during early life.41,42 Post-discharge health care utilization was characterized by 
hospital readmissions, emergency department visits, and outpatient visits during a period 
of 365 days after discharge. In addition, this study evaluated the association between the 
severity of NOWS and how it affected health care utilization post-discharge. This study 
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utilized the Cerner Health Facts® (HF) database which includes de-identified electronic 
health records (EHR) from 872 participating CERNER hospital and clinics in the U.S. 
(years 2011-2017). We hypothesized that infants who were diagnosed with NOWS at 
birth would have higher post-discharge health care utilization compared to infants 
without NOWS. Additionally, we hypothesized that pharmacological management of 
NOWS, use of adjunctive therapy (indices of NOWS severity) along with LOS and 
other medical conditions related to NOWS would be associated with overall increased 
post-discharge health care utilization. To test these hypotheses we proposed the 
following Specific Aims: 
1.6 Specific Aims 
Aim 1: To compare and characterize post-discharge health care utilization of infants 
born with NOWS compared to controls (uncomplicated births and late preterm 
births) during a one-year follow-up period.  
Hypothesis 1: Infants born with NOWS will show significantly higher post-discharge 
health care utilization compared to both control groups owing to the exposure to opioids 
in utero, and during the management of NOWS.  
Aim 1 will be evaluated through the following sub-aims: 
1.A) To compare the hospital readmissions in infants born with NOWS to controls. 
1.B) To compare the emergency department visits in infants born with NOWS to 
controls.  
1.C) To compare the outpatient visits in infants born with NOWS to controls. 
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Aim 2: To evaluate the relationship between NOWS severity measures 
(pharmacologic management of NOWS, use of adjunctive therapy, concurrently 
diagnosed complications associated with NOWS, and hospital length of stay) and 
post-discharge health care utilization in the one-year follow-up period 
Hypothesis 2: Markers of severity of NOWS, including, but not limited to, pharmacologic 
treatment administered, use of adjunctive therapies (phenobarbital, clonidine), and LOS 
will be associated with increased health care utilization over the one-year follow-up 
period.  
Aim 2 will be carried out through the following sub-aims: 
2.A) To evaluate the relationship between NOWS severity measures and hospital 
readmissions. 
2.B) To evaluate the relationship between NOWS severity measures and 
emergency department visits 
2.C) To evaluate the relationship between NOWS severity measure and outpatient 
visits. 
1.7 Significance 
The rates of NOWS in the United States has been constantly rising owing to the 
opioid epidemic plaguing the country.43 A majority of the infants diagnosed with NOWS 
will require treatment and longer hospitalization placing a significant burden on the 
healthcare system.37,43 It is also important to note that almost 80% of the births associated 
with OUD in pregnancy are paid for by Medicaid leading to an immense financial stress 
on the social welfare system.25,44 While extensive studies have been conducted to minimize 
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the burden on the health care system during the initial management of NOWS, the potential 
long-term impact of such interventions has been relatively overlooked.26,27,29,39 Only a 
single prior study used balancing measures such as 30-day all-cause readmission, 30-day 
readmission related to NOWS, and death or unexpected ICU transfer within 30 days to 
measure the long-term effectiveness of the intervention.45 Additionally, there are relatively 
few studies that evaluated long-term health care utilization in infants born with NOWS. A 
recent paper by Patrick et al. reported that infants with NOWS had a higher risk of hospital 
readmissions compared to controls.36 However, the study did not include any information 
on the medications that the infants received during their hospital stay. Prior report suggests 
that variations exist in the treatment of NOWS, hence, detailed examination of treatment 
received by the infant for NOWS and its association with post-discharge health care 
utilization are critical.37 
Our study expands on the work previously done by Patrick et al. by the addition of 
variables that quantifies the treatment received by the infants for NOWS along with 
severity measures of the condition. The administrative data used by Patrick et al. lacked 
clinical data related to the treatment of NOWS which limited the study findings. The 
availability of clinical information in the HF data overcomes those limitations by 
elaborating on specific treatment received by the infants during the management of NOWS 
and its effect on the health care utilization in the future. This study also provides a 
comprehensive comparative summary of post-discharge health care utilization in infants 
with and without NOWS. The model assessing the severity of NOWS (based on treatment 
received, LOS and other variables) and post-discharge health care utilization will be a 
valuable resource in developing interventions leading to improved health outcomes that do 
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not merely focus on reducing hospital stay but also minimizing long-term adverse events 
in infants born with NOWS. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
In this chapter, a detailed review of NOWS is presented. In the first section, a 
description of NOWS will be provided, followed by an account of tools used to assess 
NOWS. Next, we discuss the management of NOWS. These topics will provide us an 
insight into the etiology, assessment, and treatment of NOWS in infants. Additionally, 
further insight into how long-term outcomes may manifest in infants with NOWS is 
provided. Finally, a detailed literature review of long-term health care utilization in infants 
with NOWS is presented.  
2.2 Neonatal opioid withdrawal syndrome 
Opioids are natural, synthetic or semisynthetic compounds that act on the opioid-
receptors (mu, kappa, and delta) in the central nervous system (CNS) to produce 
analgesia.46 They also produce effects such as euphoria, sedation, and depression of 
respiratory and gastrointestinal functions. Noradrenaline release is acutely inhibited in the 
synaptic terminal due to long-term opioid use. However, the rate of noradrenaline release 
in the synapses returns to normal after prolonged exposure and tolerance to opioid develops 
in chronic users.32 Discontinuation of opioid use then results in abnormal release of 
noradrenaline which produces the signs of withdrawal. 
Opioids are lipophilic compounds that can cross the placental and blood-brain 
barrier. Hence, prenatal opioid use affects the fetus. Active use of illicit opioids in during 
pregnancy has been associated with adverse birth outcomes in the infant, such as low birth 
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weight, and put the infant at additional risk because of other risky health behaviors related 
to active substance use.47,48  
Treatment with methadone or buprenorphine is a preferred treatment of OUD in 
pregnancy and is designed to manage cravings, prevent withdrawal symptoms, and 
minimize stress to the fetus.49 Pharmacological treatment is often accompanied by a wide 
variety of prenatal care services that help to maintain physical and mental well-being of 
the pregnant woman. While treatment with MAT, such as methadone, has substantial 
benefits compared to illicit opioid use, it does not guarantee successful abstinence and 
might be associated with significant, prolonged withdrawal effects in the newborn.32  
A recently published systematic review concluded that the current evidence did not 
support detoxification as a viable intervention in pregnancy as it increased the risk of 
relapse.50 Wang et al. also reported that detoxification during pregnancy increased the risk 
of relapse and illicit drug use.51 However, the study also concluded that detoxification 
treatment did not affect the rates of NOWS or preterm birth. 
Approximately 55 to 95% of the newborns with in-utero exposure to opioids 
develop postnatal withdrawal or NOWS.32,52 NOWS is a complex physiological disorder 
that involves the nervous system (central and autonomic) and gastrointestinal system of the 
infant. While NOWS is a preferred term that defines opioid withdrawal in infants, the term 
Neonatal Abstinence Syndrome (NAS) is also widely used to describe withdrawal in 
infants. However, the term is not considered technically correct as the term “abstinence” 
suggests “intention” and infants are not capable of intentional understanding or action.53 In 
addition, NAS can refer to withdrawal syndrome associated with other drugs.  
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Clinical manifestation of NOWS can be broadly classified into three categories: a) 
metabolic, vasomotor, and respiratory, b) gastrointestinal and c) CNS.52-55 The first 
category is associated with symptoms, such as fever, sweating, mottling, and tachypnea. 
Gastrointestinal expressions are characterized by vomiting/regurgitation, diarrhea, weight 
loss, and poor feeding. CNS manifestations are characterized by tremors, disturbances in 
sleep, crying, irritability, and seizures. The symptoms of NOWS develop typically in 24 to 
96 hours after birth; however, time of onset, and severity varies depending on multiple 
factors. While time to onset of NOWS could have multiple predictors, dose and half-life of 
the opioids that the infant was exposed to in-utero play a vital role in explaining the 
variability. Symptoms may develop later in infants who were exposed to opioids with a 
longer half-life period (e.g., methadone/buprenorphine) compared to opioids with a shorter 
half-life period (e.g., heroin). Symptoms attributable to NOWS from heroin use are often 
seen within 24 hours after birth. In comparison, symptoms of withdrawal from methadone 
may occur 24 to 72 hours after birth.18 In buprenorphine exposed infants, the onset of 
withdrawal is around 40 hours after birth.56,57 While NOWS is more common in infants 
exposed to methadone compared to buprenorphine, studies have shown that up to 50% of 
the infant exposed to buprenorphine develop NOWS.32,49,57,58 Factors, such as exposure to 
other drugs, tobacco use, maternal nutrition, stress, opioid metabolism rates, and preterm 
delivery, may also affect the severity of NOWS.59-61 Based on such observations, the 
American Academy of Pediatrics has recommended an in hospital observation period of 3 
to 7 days in neonates with in-utero exposure to opioids.32 
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2.3 Assessment of NOWS 
Assessment of neonates who develop symptoms of NOWS is critical to quantify 
the severity of withdrawal, thereby providing a guide to its management. Several tools have 
been developed to help in the assessment of NOWS in newborns. The Finnegan Neonatal 
Abstinence Scoring Tool (FNAST) was the first tool developed to assess the severity of 
NOWS.52 It consists of 21 items and the possible score ranges from 0 to 62. Pharmacologic 
management of NOWS is usually recommended if the infant scores more than or equal to 
8 on three consecutive evaluations or 12 or more on two consecutive evaluations. While it 
is the first and most widely utilized tool to score the severity of NOWS, it has been 
criticized for its complexity and length.62 Additionally, lack of validation and suboptimal 
inter-rater reliability of the tool are concerning.63 After the first Finnegan tool was 
developed, three other scoring tools, i.e., The Lipsitz Neonatal Drug Withdrawal Scoring 
System, the Neonatal Narcotic Withdrawal Index, and the Neonatal Withdrawal Inventory, 
were developed between 1975 and 1998.64-66 They consist of a limited number of items (7-
11) for simplicity and rapid administration. In 2010, the FNAST was modified into the 
MOTHER NAS scale which was utilized in the MOTHER randomized clinical trial 
study.49 It is a 19-item scale with scores ranging from 0 to 42; the score required for 
treatment initiation is 9 or higher. In 2013, a shorter version of the FNAST, called the 
Finnegan Neonatal Abstinence Syndrome Scale-Short Form, was developed. It allows for 
faster assessment with fewer items and consists of 7 items with scores ranging from 0 to 
16.67 Treatment initiation with opioids is recommended at a score of 8 or higher. Recently, 
another approach, called Eat, Sleep, and Console (ESC), was developed by Grossman et 
al. for evaluation and treatment of infants with NOWS.26 It utilizes a novel approach that 
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evaluates three criteria: eating (infant was able to eat ≥ 1 oz. per feed), sleeping (infant was 
able to sleep undisturbed ≥1 hour), and consoling (infant was able to be consoled within 
10 minutes if crying). Infant meeting these criteria is considered “well managed” and 
requires no further intervention. Evidence from recent studies support ESC method to 
minimize exposure to pharmacological treatments and decrease the LOS.68 
Another tool, known as the Neonatal Network Neurobehavioral Scale (NNNS) part 
II (Stress and abstinence scale) was developed in 2004.69 The NNNS is a comprehensive 
instrument developed to examine outcomes in newborn after prenatal exposure to drugs. 
The stress/abstinence scale of the NNNS consists of 7 categories and consists of fifty items. 
It is important to note that this tool was not developed to be used as a guide for the treatment 
of NOWS but rather as a comprehensive newborn evaluation. 
2.4 Management of NOWS 
The objective of management of NOWS is to promote growth and development of 
the infant. Particular importance is given towards minimizing distress, improving food 
intake, and promoting mother-child bonding. While NOWS has been managed for over 
four decades there is lack of consistency in management protocols across different 
hospitals. In general, care to infant diagnosed with NOWS should include a 
multidisciplinary approach that includes non-pharmacologic and pharmacologic 
management based on the needs of the mother-infant dyad in an environment that is non-
judgmental and fosters mother-infant bonding.70 It is essential to note that the creation of a 
safe environment for the mother is equally important as there is significant stigma related 
to opioid use and withdrawal effects in the infants. Also, active participation of mothers in 
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the healing process by rooming-in and breastfeeding (when appropriate) has shown to 
benefit the mother-infant dyad.63,71 Since maternal characteristics (e.g.: polysubstance use, 
presence of other comorbidities, low socio-economic status, stress, poor nutrition etc.) and 
environment are considered risk factors for poor health outcomes in those infants, post-
partum support mechanism for the mother may be required to ensure the adequacy of care 
in the newborn.  
2.4.1 Non-pharmacologic care 
Infants who are prenatally exposed to opioids initially receive supportive care. Such 
care involves creating a gentle non-stimulating environment to calm the infant and promote 
rest.32,53,59,63 It involves minimizing exposure to stimuli, such as light and noise, 
minimization of handling, promoting feeding to improve weight gain, and resting.32 While 
several alternative care methods, such as massage and cuddling, have been utilized in the 
management of infants with NOWS, those intervention have not been rigorously assessed 
for their efficacy in reducing severity of NOWS. There is consistent evidence that supports 
breastfeeding and rooming-in to improve outcomes associated with NOWS.71,72 Infants 
who were breastfed were shown to require less treatment with opioids and had a shorter 
LOS compared to infants who had received formula.73,74 Unfortunately, rates of 
breastfeeding in mothers receiving treatment for OUD are low.75 It is important to note that 
breastfeeding is contradicted in mother with HIV infection and illicit drug use, and such 
conditions are common in OUD. Additionally, infant exposure to opioids continues 
through breast milk, even though in very small amounts. Although the benefits of 
breastfeeding and rooming-in have been shown consistently, potential barriers to their 
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implementations, such as differences in the practice setting, unavailability of resources, 
and reluctance to introduce new practices, exist.53 
2.4.2 Pharmacologic treatment 
More than two-thirds of the infants with NOWS have limited response to non-
pharmacologic management and hence require pharmacologic treatment for the 
management of the symptoms.23,53 The rationale behind the use of pharmacologic treatment 
is short-term management of the symptoms, such as seizures, fever, and weight loss 
associated with NOWS, as drug withdrawal is self-limiting in nature.32 There is significant 
variation in the management of NOWS and there is no specific standard of care that is 
widely accepted in relation to dosing, treatment initiation or use of adjunctive therapies.37 
There is a consensus on the use of oral morphine or methadone as first-line agents for the 
management of NOWS.33 Morphine is a short-acting mu-opioid receptor agonist, and 
methadone is a much longer acting synthetic mu-opioid receptor agonist. While these 
medications have been consistently shown to be effective in the management of NOWS, 
their use is often associated with longer hospital stays. Side effects, such as sedation and 
depression of respiratory functions, are also common.23,53 Studies also report that 
regardless of the opioid used for the treatment of NOWS, a structured protocol for 
treatment is significantly likely to lower treatment days, LOS, and result in lower doses of 
opioid administered to the infant.76,77  
Adjunctive agents, such as phenobarbital and clonidine, are used if the infant fails 
to respond to the first-line agents. There are no specific guidelines for the addition of these 
second-line agents in the management of NOWS.38 Studies on long-term safety and 
efficacy of these agents are also currently lacking.29 
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2.5 Long-term neurobehavioral and clinical outcomes associated with NOWS 
There have been several reviews that highlight long-term neurobehavioral and 
clinical outcomes associated with prolonged in-utero opioid exposure in infants.67,78,79 
Studies have reported that problems with vision, such as strabismus, reduction in visual 
acuity and other impairments, are related to opioid exposure.80-82 Research on behavioral 
and cognitive development in infants born to mother with OUD show conflicting results. 
Two reviews which consisted of studies published prior to 2016 report poor behavioral and 
cognitive outcomes in infants prenatally exposed to opioids.78,83 However, recent studies 
on infants born to women on methadone or buprenorphine therapy showed that these 
infants had normal neurobehavioral development in early infancy.84,85  
2.6 Long-term health care utilization in infants diagnosed with NOWS 
We conducted a literature review to identify published studies that reported on 
long-term health care utilization associated with NOWS. We searched PubMed/Medline 
database using keywords related to long-term health care utilization and neonatal 
abstinence syndrome/neonatal opioid withdrawal syndrome as stated below: 
“((((((((((long-term outcome) OR long-term outcomes)) OR hospital readmissions) OR 30-
day hospital readmissions) OR emergency department visits) OR urgent care visits) OR 
healthcare utilization) OR outpatient visits)) AND ((((((neonatal abstinence syndrome) OR 
neonatal opioid withdrawal syndrome) OR opioid neonatal abstinence syndrome) OR 
neonatal abstinence) OR neonatal drug withdrawal syndrome) OR neonatal drug 
withdrawal)”.  
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Since there were limited articles that specifically evaluated long-term health outcomes 
and health care utilization in infants with NOWS, we also included studies that evaluated 
these outcomes infants with in-utero opioid exposure. This allowed for comparison of 
outcomes in infants with NOWS with infants who had in-utero opioid exposure regardless 
of the diagnosis of NOWS. The inclusion criteria for the literature review included: 
1) Study investigating long-term health care utilization associated with 
NOWS/NAS/maternal opioid exposure 
2) Human studies 
3) Studies published in English 
The exclusion criteria for the review included: 
1) Literature review 
2) Comment on a published article 
3) Withdrawal unrelated to opioids 
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Figure 1: PRISMA flow diagram for literature review 
 
 
Based on our search criteria, our initial search led to the identification of 131 studies 
(Figure 1). Of these studies, 24 studies that were relevant to the literature search were 
identified and were further screened. Three articles were selected from the 24 studies after 
evaluation. Three more studies/reports were identified after reviewing the references in 
selected studies. In the sections below 6 articles that evaluate long-term health care 
utilization in infants born with NOWS/NAS are described (Table 1). 
Cordelie E.W. evaluated the association between NAS and long-term health 
outcomes.35 Using a retrospective cohort design, the researchers studied infants born in the 
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state of Washington between the years 1990 and 2008 evaluating the risk of hospital 
readmissions in infants with and without NAS. The follow-up period was five years after 
discharge from the hospital. The study reported that infants diagnosed with NAS were at a 
significantly higher risk of hospital readmission compared to unexposed infants even after 
controlling for factors such as maternal age, education, gestational age, and smoking. After 
adjustment for the confounders, the authors reported that infants diagnosed with NAS had 
a higher risk of hospital readmission associated with a) infectious and parasitic diseases, b) 
diseases of the nervous, gastrointestinal and genitourinary system, and c) injury by another 
person, neglect or abuse.  
Stephen W.P. et al. evaluated the risk of hospital readmission in infants who were 
diagnosed with NAS.36 The study utilized administrative data for all the births in the state 
of New York from 2006 to 2009 to identify infants with a NAS diagnosis and two 
comparison groups - uncomplicated term births and late preterm births. After adjusting for 
confounders, the study showed that there was a higher risk of 30-day hospital readmission 
in the infants with NAS compared to infants with uncomplicated term births. They also 
stated that the readmission rates were similar to late preterm infants. Additionally, infants 
who received a diagnosis of NAS but were discharged in less than a week since birth had 
a higher 30-day hospital readmission rate. 
Tamara C. et al. reported on the child health services utilization in children born to 
119 mother with substance use disorder (self-reported use of methadone, amphetamine or 
opiates) in the period between 2000 and 2003 in Australia.86 They reported that 
approximately 29% of the children who were born to mothers with substance use disorder 
did not access standard health services in their first two years of life. Additionally, use of 
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child health services was associated with lower child protection notification for mothers 
who were on methadone compared to other substances.  
Kirsimarja R. et al. conducted a population-based retrospective cohort study in 
Finland to evaluate hospitalizations and “out-of-home” placements in children whose 
mothers abused substances.87 The authors followed 55,369 infants born in Finland in 2002 
for the first seven years of their lives. The study reported higher rates of injury, infectious 
diseases, hospital treatment for other reasons, and out-of-home placement in children of 
born to women with substance use disorders (n=205) compared to controls (no substance 
abuse, n=54,291). While these associations (hospitalization) were significant in unadjusted 
analysis, they remained significant in the adjusted analysis only in subjects who also had 
concomitant alcohol use. Out-of-home placement was significant (OR: 7.4, 95% C.I.: 5.2-
10.5) even after adjustment of confounders. In the adjusted model, the study controlled for 
factors such as child’s sex, mother’s psychiatric condition, relationship status, education, 
and social assistance status. 
Hannah U. et al. used a population-based retrospective cohort study to evaluate 
causes of hospitalization in children who were diagnosed with NAS at birth.88 The study 
followed children born between the years 2000 and 2011 in New South Wales for 13 years. 
They identified 3,842 infants who had received a diagnosis of NAS; the comparison group 
included 1,018,421 infants who did not have NAS diagnosis. The study reported that 
infants with NAS had a higher risk of hospitalizations (OR: 1.6, 95% C.I.: 1.5-1.7). The 
reasons for hospitalization constituted mainly of assault, maltreatment, and poisoning. 
Physiological reasons for hospital readmission were mental and visual disorders. After 
accounting for other confounders, NAS was found to be a significant predictor of 
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readmissions related to maltreatment (OR: 4.5, 95% C.I.: 3.4-6.1), and behavioral disorders 
(OR: 2.3, 95% C.I.: 1.9-2.9).  
A short report by Savin M. described health care utilization during their first year 
of life in infants who were diagnosed with NAS using the Delaware Medicaid data.34 Four 
hundred and ninety-nine infants who received a diagnosis of NAS were identified between 
the years 2012 and 2014. The study reported that approximately 15% of the infants required 
hospital readmission. There was a decreasing trend in well-child visits from 38% at six 
months to 30% at 9 months. Fifty-two percent of the infants had emergency department 
visits and 7% had urgent care visits. This report, however, lacked a control group for 
comparison.
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Table 1: Summary of articles that evaluate long-term health care utilization in infants with NOWS/NAS or maternal exposure to opioids 
Author Year Study design Study 
population 
Database Exposed 
group 
Control  Outcomes evaluated Results 
Witt CE et 
al35 
2017 Retrospective 
cohort study 
Infants born 
in 
Washington 
state (1990-
2008) 
Comprehensive 
Hospital 
Abstract 
Reporting 
System in 
Washington 
State. Data 
from both 
mother and 
infant was 
obtained 
Infants 
diagnosed 
with NAS 
(n=1,900). 
Identification 
by ICD-9-
CM code 
779.5 
Unexposed 
(n=12,283). 
Did not receive 
NAS 
diagnosis, 
neither had 
diagnosis 
codes that 
indicated 
maternal 
opioid 
dependence 
During the first five 
years of life after 
discharge 
Hospitalizations 
Infant mortality 
Adjusted relative risk 
All-cause readmission: 1.54 
(1.37-1.73) 
All-cause death: 1.94 (0.99-
3.80) 
         
Patrick 
SWS et 
al.36 
2016 Retrospective 
cohort study 
Infants born 
in New 
York State 
(2006-
2009) 
New York 
State Inpatient 
Database from 
Healthcare 
Cost and 
Utilization 
Project 
Infants 
diagnosed 
with NAS 
(n=1643). 
Identification 
by ICD-9-
CM code 
779.5 
Uncomplicated 
term births 
(n=700,643) 
and late 
preterm births 
(n=51,748) 
30-day hospital 
readmission after 
discharge 
Adjusted relative risk for 
infants diagnosed with NAS 
30-day hospital 
readmission: 2.49 (1.75-
3.55) 
         
Tamara C 
et al. 86 
2011 Retrospective 
cohort study 
Maternity 
admissions 
to Royal 
Brisbane 
Women's 
Hospital 
(2000-
2003) 
NA Mother who 
self-reported 
methadone, 
amphetamine 
or opiate use 
(n=119) 
NA During a follow-up of 
2 years: 
Child protection 
(harm: emotional, 
physical, neglect) 
Child health 
(engagement with 
any child services)  
Approximately twenty nine 
percent of the children did 
not have any child health use 
in first 2 years of life. 
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Kirsimarja 
R et al. 87 
2015 Population 
based 
retrospective 
cohort study 
Infants born 
in Finland 
(2002) 
Medical Birth 
Register (9 
additional 
registers for 
other detailed 
information) 
Mothers with 
registry entry 
related to 
substance 
abuse (1998-
2009) 
(n=202 for 
drug abuse) 
Mothers 
without 
registry entry 
substance 
abuse 
(n=53,457) 
During a follow-up of 
7 years: 
Hospitalizations  
Out-of-home 
placements 
Significant difference (drug 
abuse compared to controls) 
in unadjusted rates of: 
Injury (8% vs. 4%) 
Infectious disease (10% vs. 
7%) 
Hospital treatment for other 
reasons (51% vs. 36%) 
Out-of-home care (38% vs. 
1%)          
Hannah 
U88 
2015 Population 
based 
retrospective 
cohort study 
Infants born 
in New 
South 
Wales 
(2000-
2013) 
Linkage of 
Perinatal Data 
Collection, 
Admitted 
Patient Data 
Collection, 
Australian 
Bureau of 
Statistics Cause 
of Death, 
NICUS Data 
Collection 
Infants 
diagnosed 
with NAS 
(n=3837). 
Identification 
by ICD-10 
code p96.1. 
Infants without 
NAS 
(n=1,016,565) 
During a follow-up 
for a maximum of 13 
years: 
Hospitalizations 
Reasons for 
hospitalizations 
Risk of outcomes compared 
to controls: 
Rehospitalization (OR: 1.6, 
95% C.I.: 1.5-1.7) 
Mortality during 
hospitalization (OR: 3.3, 
95% C.I.: 2.1-5.1) 
Reason for hospitalization: 
Assaults, maltreatment, 
poisoning, behavioral 
health, vision problems. 
         
Savin M34 2017 Retrospective 
study 
Infants born 
in Delaware 
(2012-
2014) 
Delaware 
Medicaid data 
Infants 
diagnosed 
with NAS 
(n=499). 
Identification 
by ICD-9-
CM code 
NA During the first year 
of life: 
Emergency 
department visits 
Urgent Care visits 
Primary care provide 
visits 
Well child visits 
Health care service 
utilization rates: 
Inpatient: 15% 
Emergency department: 
52% 
Urgent Care: 7% 
No vaccinations: 8% of 
infants 
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From the studies above, we can conclude that there is increased health care 
utilization in infants with a NAS/NOWS diagnosis or those exposed to opioids prenatally. 
The studies show increased need for care and follow-up services in infants who received 
such diagnoses. While these studies have shown that withdrawal syndromes can have far-
reaching consequences, the results of the studies lack clinical data and are generalized to 
specific regions. Additionally, most of these studies were not nuanced to capture the 
specific details of health care utilization, such as emergency department visits and 
outpatient visits. Inpatient visits are more likely in infants who were diagnosed with 
NAS/NOWS as noted by those studies, but well-child visits and child care services have 
been shown to be underutilized. Our study addresses many of these limitations. First, the 
dataset represents a diverse population. Second, it evaluates a broader range of health care 
utilization events. Finally, it also incorporates clinical data derived from the electronic 
health records in the analysis.  
Likewise, prior studies have not specifically focused on the treatment received by 
the infants after birth during their hospital stay and how it could potentially affect health 
care utilization in the long run. Opioids used for the treatment of withdrawal symptoms 
and adjunctive therapy may have a long-term effect on the infants that may lead to 
increased health care utilization. Since a large variability in treatment protocol exists, it is 
essential to know how such differences might affect long-term health care utilization. 
Further, studies that focus on the management of NOWS have primarily focused on 
minimizing the exposure to opioids and LOS in the hospitals without accounting for 
hospital readmission rates and health care utilization in the future.35,36 This might lead to 
increase in rates of hospital readmission in infants who were diagnosed with NOWS. In 
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some infants, the full symptoms of NOWS could possibly manifest after 4-5 days; any 
discharge before that period could lead to further health care utilization in terms of 
emergency department visits. For example, the study by Patrick et al. demonstrated that 
the rate of emergency department visits are higher in infants with NAS who were 
discharged before one week since birth compared to those discharge after one week.36  
Additionally, it is important to be able to compare long-term health care utilization 
of infants with NOWS to other medical conditions that are known to be self-limiting in 
nature, but are associated with higher health care utilization. Late preterm infants are born 
at a gestational age of 33 weeks or higher but less than 37 weeks.89 These infants are known 
to be physiologically “immature”. They are at a higher risk of morbidity, mortality, and 
hospital readmission compared to term birth infants.89 These infants may exhibit symptoms 
similar to infants with NOWS, such as respiratory distress and feeding difficulties during 
their birth hospitalization, although the mechanisms vary greatly from infants with NOWS. 
Late preterm infants can serve as an efficient control group for infants with NOWS. 
Therefore, it was included in our study as secondary control group  
While it is important to note that long-term outcomes are difficult to ascertain given 
that there are several factors (environmental and social) associated with OUD, the current 
gap in the literature regarding long-term health care utilization and treatment received 
during the management of NOWS should be explored. Understanding the differences in 
health care utilization in infants who were diagnosed with withdrawal syndrome and 
evaluation of their health care utilization will lead us to better understand the long-term 
consequences of NOWS. It is imperative that proper follow-up of the mother-infant dyad 
is maintained to promote child safety and health. In the context of the current opioid 
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epidemic in the United States, our study will be able to specifically estimate the long-term 
burden of NOWS which can help in planning intervention or allocation of specific 
resources for combating the affliction.  
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CHAPTER 3: METHODS 
3.1 Introduction 
In this chapter, approach to the analysis of data to test our hypothesis is outlined. 
This section begins with the description of the data source that was used in the study, 
followed by the study design, and inclusion and exclusion criteria for sample section. Then 
the methods for each Specific Aim are described, including methodology for identification 
of outcome and exposure variables. Finally, statistical methods used in the analysis are 
described which is followed by power analysis for sample size calculations.  
3.2 Data source 
The Cerner Health Facts® database was utilized to assess the differences in post-
discharge health care utilization in infants born with NOWS compared to controls during 
a one-year follow-up period. HF is a national database warehouse that collects extensive 
clinical data across hospitals in the United States that utilize the Cerner EHR System. The 
database includes encounter data consisting of emergency, outpatient, and inpatient visits. 
Further, information on provider specialty, hospital procedures, diagnoses, laboratory, and 
pharmacy data are included in the HF database. Additionally, patient demographic 
information, such as age, sex, and race, along with hospital characteristics, such as 
specialty, acute care, number of beds, census region, and location (urban or rural), are 
available. HF database is de-identified and HIPAA-compliant which allows for protection 
of both patient’s and organization’s identity. The database is longitudinal and continuity of 
patient encounters, if it occurred within the same health system, is preserved. This allows 
for efficient follow-up of patients after discharge when they seek health care in the same 
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health system. HF database consists of records from over 500 health facilities in the United 
States with records dating back over two decades. IRB approval from the University of 
New Mexico Health Sciences Center Human Research Protection Office was obtained for 
this study. 
 For purposes of this analysis, HF data between the January 1, 2011 and September 
30, 2017) were used. This time captures the increasing rates of opioid use in the U.S. and 
subsequent increase in the rate of NOWS.90  
3.3 Study design 
Our study utilized a retrospective cohort study design. The study population 
consisted of all the births recorded in the HF database between January 1, 2011 and 
September 30, 2016. Study cohort was sampled from the study population based on 
inclusion/exclusion criteria listed in the sections below. Retrospective cohort study design 
allowed for examination of several outcomes in the given sample.  
3.4 Study population 
3.4.1 Selection criteria for infants diagnosed with NOWS (exposed group) 
Inclusion criteria: 
Infants diagnosed with NOWS were identified using the International 
Classification of Diseases, Ninth Revision (ICD-9-CM) diagnostic code 779.5 and ICD-10 
diagnostic code P96.1, which denote drug withdrawal syndrome in infants. Encounter 
identification number (EIN) is a unique identification number assigned to a specific 
encounter of a patient with the health care system. Based on the EIN, patient number for 
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that specific visit was determined and traced back to the unique patient identification 
number (PIN). The unique PIN was used to follow-up the cohort to assess their post-
discharge health care utilization. The follow-up assessment period began on the discharge 
date associated with the encounter that was related to NOWS and ended after 365 days. 
Exclusion criteria: 
We excluded infants whose initial LOS after birth was less than 3 days. This 
criterion was used following the rationale that infants with suspected NOWS often have a 
required observation period of 72 to 96 hours.32,91,92 Previous studies have also reported 
that adding an additional criterion regarding LOS could improve the identification of 
infants with NOWS.93 We also excluded infants whose age at first encounter was more 
than 4 days. This period was chosen to account for any infants with NOWS who were 
transferred into a CERNER facility but not born in that hospital. Critically-ill neonates are 
often treated with opioids which may result in iatrogenic withdrawal syndrome. Since the 
objective of the study is to evaluate health care utilization in infants with NOWS 
subsequent to in-utero exposure to opioids, we excluded infants with following conditions: 
lung disease, intraventricular hemorrhage, periventricular leukomalacia, necrotizing 
enterocolitis, spontaneous bowel perforation, congenital anomalies, and those that required 
critical oxygenation (Table 2). These diagnoses are presumed to be linked with iatrogenic 
NOWS.25,36,37 Infants with early preterm birth (gestational age at birth less than 33 weeks) 
were also excluded as they could potentially have a much longer hospital stay and have a 
large set of comorbidities. Infants with total LOS of more than 60 days were also excluded 
from this study group as outliers. We also excluded patients whose discharge summary 
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denoted that the patient had passed away or if they were transferred to a health 
center/hospital. 
3.4.2 Selection of the control groups: 
Uncomplicated births: 
Uncomplicated births were identified using ICD-9-CM code V30.x and ICD-10 
code Z38.0 which apply to “Single liveborn, born in hospital, delivered without mention 
of cesarean section.” We excluded infants with LOS less than 0 days (to account for 
inaccuracies in information regarding LOS) and infants whose age at first encounter was 
more than 4 days. Additionally, infants with initial LOS of more than 3 days were also 
excluded. Prolonged hospital stay after birth is a marker for an underlying condition that 
could require clinical observation, tests or management. Exclusion of infants with LOS 
longer than 3 days ensured that such cases were excluded from the uncomplicated birth 
study group. We also excluded infants who had received additional diagnosis of NOWS, 
diagnosis codes related to iatrogenic NOWS, or any preterm birth (gestational age less than 
37 weeks) from this group. Patients whose discharge summary denoted that the patient had 
passed away or if they were transferred to a health center were also excluded.  
Late preterm births: 
Infants with late preterm births served as secondary controls to the exposed group. 
These infants are susceptible to adverse health outcomes and have increased hospital 
readmissions compared to term infants, but are not as ill as very preterm infants.41,42,94 
These infants were identified using the ICD-9-CM codes 765.27 and 765.28 (ICD-10: 
P07.36- P07.39), which represent gestational ages greater than or equal to 33 weeks and 
less than 37 weeks.89 Since infants with NOWS are likely to be born preterm, these two 
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study groups were devised to be mutually exclusive, i.e. infants diagnosed with NOWS 
were not categorized as late preterm birth. Infants with LOS less than 0 days were excluded 
from this study group. We also excluded infants whose age at the encounter was more than 
4 days. Furthermore, we excluded patients whose LOS was more than 60 days. We also 
excluded patients whose discharge summary denoted that the patient had passed away or 
if they were transferred to a health center. 
  
33 
 
Table 2: Conditions for inclusion and exclusion criteria for sample selection and 
corresponding diagnostic codes (ICD-9-CM and ICD-10-CM) 
Condition ICD-9-CM ICD-10-CM 
NOWS/NAS 779.5 P96.1 
   
Late preterm births   
Preterm newborn, 
gestational age 33-34 
completed weeks 
765.27 P07.36, P07.37 
Preterm newborn, 
gestational age 35-36 
completed weeks 
765.28 P07.38, P07.38 
   
Single live-born, born in 
hospital, delivered without 
mention of cesarean section 
V30.00 Z38.0 
   
Exclusionary codes   
Chronic respiratory disease 
arising in the perinatal 
period 
770.7 P27.X 
Intraventricular hemorrhage 
of fetus or newborn 
772.1X P52.X 
Periventricular 
leukomalacia 
779.7 P92.1 
Intracranial injury of other 
and unspecified nature 
854.XX S06.90XA, S06.89XA 
Necrotizing enterocolitis in 
newborn 
777.5X P77.1-3, P77.9 
Perinatal intestinal 
perforation 
777.6 P78.0 
Early preterm, gestational 
age less than 33 weeks 
765.21-765.26 P07.21- 26, P07.31-35 
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3.4.3 Detailed description of the sample selection process for the study 
HF dataset was accessed using a secure access point at the University of New 
Mexico Clinical and Translational Sciences Center. The database consists of several data 
tables linked through a primary encounter identification number. To account for the large 
number of observations across several years that spans three different cohorts, the initial 
data cleaning process was divided based on the study group and the year of the encounter. 
Using Postgres SQL, the first selection criterion was applied to identify the study groups. 
For example, infants with NOWS were identified using the type of code (ICD-9 or 
ICD-10) and the diagnosis code (779.5 or P96.1) from the “diagnosis and procedure 
specific information table”. Additionally, the selection criteria were also restricted to 
discharge between specific time period (e.g., discharges between 2011 and 2012). For 
simplicity, the dataset created in this step will be referred to as “base set” in the manuscript. 
After the specific EINs were collected for the specific study group and for a specific 
year (or time period), unique PIN associated with the EIN for each infant in the base set 
was identified. These PINs were then used to collect all of the encounter related 
information of an infant for a period of one year starting at the initial index period for the 
search. For simplicity, the dataset created in this step will be referred to as “complete set” 
in the manuscript. 
The dataset that was created (complete set) contained information on diagnostic 
codes, age that the specific encounter, hospital information (census region, census division, 
bed size range, urban-rural status), patient type, care-setting, admit date, discharge date, 
admission type, discharge description, and information on the infant (race, sex). The 
35 
 
dataset thus created was in a long form, i.e. each encounter along with any number of 
diagnostic codes or information that varied across that specific encounter were presented 
in different rows. These individual data files were exported as *.csv file and processed in 
STATA (version 14, College Station, TX).95  
The raw dataset extracted from the full HF database was processed in five steps 
which are described below (illustrated in Figure 2): 
a) Preprocessing: Exclusion based on LOS and age at encounter criteria and identification 
of specific encounter id. 
First, raw encounter data (base set) were imported into STATA; the duplicates 
were removed. Next, LOS variable was created. This variable was calculated 
by subtracting the date of admission from the date of discharge. Following this 
step, exclusion criteria were applied based on the study group (Table 3). 
Table 3: Exclusion criteria based on age at primary healthcare encounter and LOS 
NOWS Late preterm birth Uncomplicated birth 
Age at encounter more 
than 4 days 
Age at encounter more 
than 4 days 
Age at encounter more 
than 4 days 
LOS less than 3 days LOS less than 0 days LOS less than 0 days 
- - LOS more than 4 days 
- - Patient care setting: 
NICU/ICU 
 
After the application of these exclusion criteria any remaining duplicate 
encounter IDs were excluded and a base encounter ID set was created.  
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b) Identification of the primary encounter and associated diagnostic codes. Application of 
diagnostic codes based exclusion criteria. 
The base encounter ID set was merged with the “complete set” and matched 
records were retained. The resulting dataset was in a long form and contained 
all the primary visit related information. This dataset was converted to a wide 
form (diagnostic codes from rows to columns). Following the transformation, 
diagnostic codes based exclusion criteria were applied (Table 4). This set will 
be referred to as “baseline encounter set” for future reference. 
Table 4: Exclusion criteria based on diagnostic codes and LOS 
NOWS Late preterm birth Uncomplicated birth 
Exclusion criteria 
Iatrogenic NOWS Iatrogenic NOWS Iatrogenic NOWS 
Early preterm 
(Gestational age <33 
weeks) 
Early preterm 
(Gestational age <33 
weeks) 
Any preterm  
(Gestational age <37 
weeks) 
 Diagnostic codes for 
NOWS 
Diagnostic codes for 
NOWS 
LOS more than 60 
days 
LOS more than 60 
days 
- 
 
After the application of the exclusion criteria, unique patient identification 
numbers were selected from the dataset to identify infants who would be 
eligible for follow-up.  
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c) Identification of the follow-up visits using the unique patient identification code. 
Quantification of the outcome variables (post-discharge health care utilization) and the 
time to events for a specific outcome. 
The unique patient identification number set was merged with the “complete 
set” and the matched records were retained. This dataset consisted of all the 
encounter related information with the PIN across multiple health related 
encounters in a long format. The dataset was converted to a wide format 
accounting for the diagnosis code related to each encounter. Next, the dataset 
was sorted using the admit date and PIN. Time-to-event variable was created 
by subtracting unique date of admission/ date of event (post-discharge events) 
from the date of discharge related to the primary visit. An event counter variable 
was created to calculate the number of post-discharge health care utilization 
event. Since the above algorithm would also create a time-to-event for the 
baseline (which would be equal to the LOS), the value was specified as zero. 
The value zero for the time-to-event marked the primary/baseline health 
encounter. Next, the follow-up event or post-discharge health care utilization 
event were categorized into 3 variables (Inpatient, Emergency, Outpatient) 
using the patient care-setting and patient type variables originally present in the 
HF database. These new variables were retained along with EIN and PIN to 
create a temporary dataset. The temporary dataset was transformed to a wide 
format. After the conversion, each unique patient (observation unit) had all the 
health care utilization events in a single row. Following this step, binary 
variables were created for presence of each event (Inpatient, emergency, 
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outpatient) for event taking place within 365 days of discharge. This set will be 
referred to as “outcomes set” in the manuscript. 
d) Merging initial encounter information (baseline data) with the post-discharge health 
care utilization data. 
The baseline information form “baseline encounter set” was merged with the 
“outcomes set” using the unique patient identification number. Duplicate 
matches were excluded.  
e) Merging data across study group and study years to get a final working database for 
statistical analysis. 
Data across all the study group for all the study period were appended. The data 
from the uncomplicated group consisted a 25% random sample (randomly 
sampled from each year). Additional exclusion criteria for infants who were 
recorded as “Expired” or “Readmitted” in the initial visit discharge summary 
was applied during this step. Finally, a second reexamination for duplicate 
encounters or unique IDs was performed and duplicates were removed.  
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Figure 2: Graphical illustration of the data cleaning, merging, and modification for the 
study 
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3.5 Aim 1: To compare and characterize post-discharge health care utilization of infants 
born with NOWS compared to controls (uncomplicated births and late preterm births) 
during a one-year follow-up period.  
For Aim I, the study cohort was identified, as previously described. The follow-up period 
for the cohort began at the time of discharge and ended at 365 days after discharge (Figure 
3).  
3.5.1 Outcomes 
The outcomes of interests are described in the following section (Table 5). For Aim 
1.A, the outcome of interest was post-discharge hospital readmission. These visits were 
assessed using the patient type and patient discharge care setting variable in the HF 
database. Hospital readmission was operationalized using four different variables. First 
was an indicator variable for any readmission within 30 days of discharge. Second was any 
readmission during the total follow-up period of 365 days. Third was the total number of 
readmissions during the study period. Lastly, we calculated time to first hospital 
readmission as the fourth outcome variable.  
 For Aim 1.B, the outcome of interest was post-discharge emergency department 
visit. These visits were assessed using the patient type and patient discharge care setting 
variable. Emergency department visit was operationalized by four different variables. First 
was an indicator variable for any emergency department visit within 30 days of discharge. 
Second was any emergency department visit during the total follow-up period of 365 days. 
Third was the total number of emergency department visits during the study period. The 
fourth was time to first emergency department visit.  
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For Aim 1.C, the outcome of interest was outpatient visits. They were characterized 
similarly using patient type and patient discharge care setting variable in the HF database. 
Outpatient visits were operationalized by two variables. The first was any outpatient visit 
during the study period and the second was total number of outpatient visits. 
Additionally, we constructed “any composite visit” (expressed as “any visit” in the 
tables in result section) variable which was a composite of any emergency department visit 
or hospital readmission to account for the possibility of one visit affecting other type of 
visits. 
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Figure 3: Overview of study design for Aim 1 
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Table 5: Description of the outcome variables for Aim 1 
Sub-
aim 
Description of the outcome variable Type of variable 
1.A All cause 30-day hospital readmission Binary 
1.A All cause hospital readmission during the study period Binary 
1.A Total number of hospital visits during the study period Count 
1.A Time to first hospital readmission Continuous 
1.B All cause 30-day emergency department visits Binary 
1.B All cause emergency department visit during the study 
period 
Binary 
1.B Total number of emergency department visit during study 
period 
Count 
1.B Time to first emergency department visit Continuous 
1.C Any outpatient visit during the study period Binary 
1.C Total number of outpatient visit during study period Count 
3.5.2 Covariates: 
We controlled for the infant sex, race, type of insurance, hospital location (urban or 
rural), hospital census division, year of primary encounter, and the hospital bed size as 
socio-demographic variables related to initial care. Furthermore, medical conditions, such 
as respiratory problems, feeding difficulties, jaundice, and sepsis, were also considered as 
possible covariates. Table 6 and 7 presents the operationalization of these variables.  
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Table 6: Operationalization of demographics and patient care setting covariates 
Variable Operationalization 
Sex Binary (Male and Female) 
Race Categorical (Caucasian, African 
American, Hispanic, Native American, 
Others) 
Insurance Categorical (Medicaid, Commercial, 
Others) 
Census division Categorical (1,2,3,4,5,6,7,8,9) 
Urban rural status Binary (Urban, Rural) 
Bed size Categorical (Less than 100, 100-299, 
Greater than 300) 
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Table 7: Operationalization of medical diagnostic codes present at the primary health 
encounter 
Condition ICD-9-CM ICD-10-CM 
Respiratory problems   
Respiratory distress 
syndrome of newborn 
769 P22.0 
Transient tachypnea of 
newborn 
770.6 P22.1 
Respiratory condition of 
newborn, unspecified 
770.9 P28.9 
Other specified respiratory 
conditions of newborn 
770.89 P28.89 
   
Feeding difficulties 783.3, 779.31 P92.1-2, P92.8-9 
   
Jaundice 774.XX P58.XX, P59.XX 
   
Sepsis (Bacterial sepsis of 
newborn) 
771.81 P36.9 
 
3.6 Aim 2: To evaluate the relationship between NOWS severity measures (pharmacologic 
management of NOWS, use of adjunctive therapy, concurrently diagnosed complications 
associated with NOWS, and hospital length of stay) and post-discharge health care 
utilization in the one-year follow-up period 
Study sample: 
For Specific Aim 2, the sample size was restricted to infants who were diagnosed 
with NOWS at birth. They were selected based on the inclusion and exclusion criteria 
described previously in section 3.5. The overview of the study design is presented in Figure 
4. 
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Figure 4: Overview of study design for Aim 2 
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3.6.1 Measures of NOWS severity as predictors of post-discharge health care utilization 
The objective of Aim 2 was to evaluate the impact of pharmacological management 
of NOWS, LOS, adjunctive therapy, prematurity, other diagnostic codes associated with 
NOWS associated with hospital stay during the treatment of NOWS on health care 
utilization during the one-year follow-up period. These variables represented the severity 
of NOWS in the infant. Pharmacological management of NOWS was described as infant 
receiving either morphine, methadone, tincture of opium or phenobarbital during the initial 
hospital stay. Since phenobarbital is also widely used as a second line therapy, its impact 
on post-discharge health care utilization was also assessed independent of opioid treatment. 
LOS was calculated as the difference between the infant’s date of birth and the discharge 
date associated with treatment for NOWS. Other medical conditions, such as respiratory 
problems (presence of any of the conditions listed in Table 7) and feeding difficulties were 
considered as other factors relating to severity of NOWS. Furthermore, benzodiazepines, 
administered during the initial hospital stay were also considered as markers of NOWS 
severity.  
3.6.2 Operationalization of NOWS severity factors 
i. Identification of infants who received pharmacological treatment for NOWS 
 As described previously, infants who received morphine, methadone or 
phenobarbital during their initial stay in the hospital were classified as infants who received 
pharmacological treatment for NOWS. Medication used during the baseline hospital stay 
in infants with NOWS was assessed using the medication facts table in the HF database. 
First, all the encounters related to baseline visits were ascertained. Using those EIN, 
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medications used during that specific visit was identified. Medication classes were grouped 
as following: a) medications for treatment of NOWS (methadone, morphine, tincture of 
opium, phenobarbital) and b) benzodiazepines (lorazepam, alprazolam, clonazepam 
diazepam or midazolam). 
ii. Length of hospital stay 
 LOS after birth is usually considered a factor that could affect short term post-
discharge healthcare utilization.36 Length of hospital stay is a function of infant health at 
birth, i.e., presence of any medical conditions at birth can potentially lead to prolonged 
hospital stay. However, there could also be another mechanism where shorter LOS could 
lead to increased health care utilization. This could be explained in the case where a 
medical condition could potentially go undetected during the initial hospital stay which 
could lead to prompt return to a health care facility following a discharge. Furthermore, it 
cannot always be assumed that longer hospital stay is associated with poor health. For 
example, infants treated with methadone or morphine could have different LOS owing to 
the tapering schedule for the medication they received. Hence, the effect of the LOS on 
NOWS severity may not be linear. To examine if the effects of LOS are non-linear on 
short-term post-discharge healthcare utilization (30-day rehospitalization, emergency or 
composite visit), the following transformation of LOS were examined: 
a. LOS in linear form: 
In this model, the LOS was used in its original form. 
b. LOS in quadratic form: 
In this model, the LOS was used in a quadratic form, i.e., a normal form and a squared 
form of LOS were used as covariates. 
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c. LOS in quantiles: 
In this model, LOS was divided into equal quantiles (5 classes) and these quantiles 
were used as predictors. 
d. LOS as cubic splines: 
A cubic spline curve is a piecewise cubic curve with continuous second derivative. In 
our analysis we used a restricted cubic spline with 4 knots. The restriction forces the 
cubic spline to be linear at the two tails.96,97 
iii. Medical diagnostic codes assigned during the initial hospital stay: 
Medical diagnostic codes assigned to the infants at birth which are described in 
Table 7 were also considered as severity measures of NOWS. While these conditions are 
common in infants with NOWS, in the analysis we assumed that the presence of the 
diagnostic codes would mean that these symptoms were serious enough to warrant 
assigning of these specific diagnosis codes in the patients chart summary.  
3.6.3 Outcomes 
Outcomes from Aim 1 were used as the outcome of interest in Aim 2 as the scope 
of this aim was also to assess post-discharge health care utilization. Time-to-event for the 
first hospitalization and emergency department visit were not considered as outcomes of 
interest for this Aim because of the limited sample size in the NOWS group and the small 
number of events in the group.  
3.6.4 Covariates 
The covariates described in Aim 1 were used to obtain adjusted estimates in the 
second Aim. Prematurity, jaundice, sepsis, and use of antibiotics were other medical 
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covariates that were examined in the analysis. We used the sex of the infant, type of 
insurance, race, hospital location (urban or rural), hospital census division, and bed size as 
covariates in multivariable analyses.  
3.7 Sensitivity analyses  
3.7.1 Examination of the effect of LOS as a selection criterion on post-discharge 
healthcare utilization. 
 We excluded late preterm infants whose LOS was less than 3 days to make the 
study group comparable to the NOWS group. We evaluated the post-discharge health care 
utilization across these two group after the restriction to assess if the differences in post-
discharge health care utilization were a result of the difference in the exclusionary criteria. 
3.7.2 Assessment of the difference in rates of pharmacological treatment of NOWS across 
different hospitals and its impact on post-discharge health care utilization. 
 We created a binary variable to indicate if an infant was born in a hospital where 
less than 25% of infants with NOWS received pharmacological treatment for their 
condition. First, we evaluated the differences in post-discharge health care rate in NOWS 
group based on the pharmacological treatment rates in the hospitals. We then excluded the 
infants who were treated in hospitals where pharmaceutical treatment of NOWS was less 
than 25% and compared post-discharge health care utilization in this restricted group with 
the control groups. Lastly, we compared the association between pharmacological 
treatment of NOWS and post-discharge health care utilization stratified by the 
aforementioned hospital groups. 
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3.7.3 Propensity score analysis for pharmacological management of NOWS. 
A propensity score analysis was performed to account for the unmeasured 
confounding related to pharmacological treatment of NOWS. Propensity score was 
calculated for pharmacological treatment for NOWS using the following variables: sex of 
the infant, cubic form of LOS, prematurity, respiratory conditions, feeding difficulties, 
jaundice, sepsis, use of benzodiazepines, and use of antibiotics. The balancing property 
was satisfied with 10 blocks where the mean propensity score in each block was not 
statistically significant in the pharmacological treatment for NOWS vs. no 
pharmacological treatment for NOWS groups. The propensity score was used in a linear 
fixed effects model along with a binary variable for pharmacological treatment for NOWS 
to predict post-discharge health care utilization (any composite visit, any 30-day composite 
visit). 
3.7.4 Principal component analysis for NOWS severity factors. 
 To account for the multiple factors related to severity of NOWS, many of which 
were correlated, we used principal component analysis method. Principal components were 
derived using the following set of NOWS severity related variables: pharmacological 
management of NOWS, LOS, respiratory conditions, feeding difficulties, and use of 
benzodiazepines. Eigen-value >1 was used as a criterion to select components.98 These 
components were used as linear predictors to assess post-discharge healthcare utilization 
(any composite visit, any 30-day composite visit). 
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3.8 Statistical Analyses 
Baseline characteristics of the study population were presented as means for 
continuous variables, whereas, percentages were used for categorical variables. We used 
analysis of variance (ANOVA) to assess differences between the baseline characteristics 
(continuous variables) among the three study groups. For categorical variables, we utilized 
chi-square test to assess the independence of baseline characteristics across study groups.  
Statistical models for each of the Specific Aims were based on the type of outcome 
variable. For binary outcome variables, we utilized a logistic regression model. The 
primary predictor for the Specific Aim 1 consisted of the study group, whereas for the 
Specific Aim 2 the primary predictors were the severity measures for NOWS. First, we 
used a simple unadjusted binary logistic regression to quantify the association between the 
predictor variables and the outcome (Model 1). In the second step, a logistic regression 
model that included all the possible demographic covariates described previously along 
with the primary independent variable was fitted (Model 2). This step provided an adjusted 
odds ratio for the association between the predictor and the outcome variables. Finally, in 
the third step, we added the medical condition as confounders (Model 3).  
 Post-discharge health care utilization could be triggered by a variety of different 
factors. Previous studies have reported that factors, such as infant sex, race, and type of 
insurance (proxy for socio–economic condition), are possible predisposing factors that 
could affect hospital readmissions or emergency department visits in infants.99,100 
Furthermore, type of hospital, variation in health care utilization across regions and effect 
of policy changes across an extended period of time could also potentially affect the rates 
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of post-discharge health care utilization. Model 2 which incorporated these patient specific 
and hospital related variable was intended to control for these effects.  
 Model 3 was used to incorporate medical diagnoses present at birth as possible 
confounders which could affect post-discharge health care utilization in infants. Studies 
have shown that presence of respiratory problems, jaundice, infection, and feeding 
difficulties are associated with considerable risk to the infant at birth and could lead to 
higher post-discharge health care utilization.101,102 These factors were included in the 3rd 
model as we anticipated that they could potentially cause an over adjustment as these 
conditions are very common in NOWS and late preterm infants. In addition, previous 
studies have incorporated these covariates in their regression models assessing post-
discharge health care utilization,36 thereby providing a priori framework for inclusion of 
these covariates in the regression models.  
Area under the receiver operating characteristic curve (AUROC) was used to assess 
the predictive ability of the logistic regression models. The AUROC measures the ability 
of the model to correctly classify the outcome (post-discharge health care utilization) based 
on the predictors included in the model. In a logistic regression model, AUROC of 0.5 or 
50% means failed classification (no better than a flip of a coin) and AUROC of 1 or 100% 
means perfect classification.  
For Poisson regression models, we used Akaike Information Criterion (AIC)103 as 
the measure for evaluation of relative quality of statistical models. AIC of a model is given 
by the following: 
 AIC= 2k - 2ln(L) 
Where, k= number of parameters or predictors 
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 L= maximum value of the likelihood function.  
Given a set of regression models for an outcome, the model with the lowest AIC is 
preferred. In our study, we present AIC as AIC/N, where N= number of observation to 
compare the relative quality of Poisson regression models. 
 
Statistical models: 
The following equation represents the proposed logistic regression model (adjusted 
model with all the covariates) for Aim 1: 
log (
𝑝
1 − 𝑝
) =  β0 +  β𝑥I +  β𝑧Z 
Where, p = probability of outcome 
 Bx = categorical variable for study group  
 I = indicator variable representative of the categories of the study group 
 βzZ = represents the covariates in the model with their respective beta coefficients 
The null hypothesis (H0) in the model is specified as below,  
H0: βx = 0 
i.e. there is no difference in the log-odds ratio of outcome in between the control group and 
the exposed group. 
The following equation represents the proposed logistic regression model (adjusted 
model with all the covariates) for Aim 2: 
log (
𝑝
1 − 𝑝
) =  β0 +  β𝑥X +  β𝑧Z 
Where, p= probability of outcome  
 X= Row vector consisting of all the primary independent variables  
 βx= corresponding beta coefficients for the primary independent variables 
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 βzZ = represents the covariates in the model with their respective beta coefficients 
The null hypothesis (H0) in the model is specified as below,  
H0: βx = 0 
i.e. there is no effect of NOWS severity measures on post-discharge health care utilization. 
 For count based outcome variables we used Poisson regression models. In the first 
step, a simple Poisson model with the count outcome variable and the primary predictor 
variable was fitted. In the second step, a full Poisson model with all the demographic 
covariates described previously was constructed. Finally, in the third step, a full Poisson 
log-linear model along with medical conditions as additional confounders was fitted.  
A simple Poisson model for Aim 1 is specified as the following: 
Pr[𝑌𝑖 =  𝑦𝑖] =  
𝑒𝜆𝑖𝜆
𝑖
𝑦𝑖
𝑦𝑖!
 , yi  =0, 1, 2…  
The log-linear specification of the model (adjusted model) is given by: 
ln 𝜆 =  β0 +  β𝑥I +  β𝑧Z 
Where, λ = mean count of the outcome variable. 
X = categorical variable for study group 
 I = indicator variable representative of the categories of the study group 
 βzZ = represents the covariates in the model with their respective beta coefficients 
The null hypothesis (H0) in the model is specified as below,  
H0: βx = 0 
i.e. there is no difference in the log ratio of the mean number of outcomes in the control 
groups to the exposed group (infants with NOWS) after controlling for other covariates. 
The log-linear specification of the model (adjusted model) for Aim 2 is given by: 
ln 𝜆 =  β0 +  β𝑥X +  β𝑧Z 
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Where, λ= mean count of outcome variable. 
X= Row vector consisting of all the primary independent variables 
 βx= corresponding beta coefficients for the primary independent variables 
 βzZ = represents the covariates in the model with their respective beta coefficients 
The null hypothesis (H0) in the model is specified as below,  
H0: βx = 0 
i.e. there is no effect of NOWS severity measures on outcomes during the one-year follow-
up period post-discharge in infants with NOWS. The results of Poisson regression model 
are shown as Incidence rate ratio (IRR) which is obtained by exponentiating the Poisson 
regression coefficient. 
 One of the limitations of Poisson regression model is that it assumes the variance 
of the outcome is equal to its mean (or expected value). Since the outcomes consisted of 
high number of zero values we also constructed a Zero-inflated Poisson regression model 
as a robustness check to the Poisson regression. 
 For time-to-event based analysis, we first we used a Kaplan-Meier estimator to 
estimate the time-to-event (time to first health care utilization event in days).104 Kaplan-
Meier plots for time to first rehospitalization and first emergency department visits across 
the study groups were created. We then performed log-rank test of equality of time to event 
function across study groups. Finally, Cox proportional-hazards regression models were 
used to test the effect of NOWS on time to a hospital readmission or emergency department 
visits in comparison to the control groups. The following equation represents the proposed 
Cox proportional-hazards regression model (adjusted model with all the covariates for Aim 
1.A: 
ℎ(𝑡) =  h0(t) +  exp (β𝑥I +  β𝑧Z) 
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Where, h(t) = hazard function at time t 
h0(t) =baseline hazard 
 Bx = categorical variable for study group  
 I = indicator variable representative of the categories of the study group 
 βzZ = represents the covariates in the model with their respective beta coefficients 
The null hypothesis (H0) in the model is specified as below,  
H0: βx = 0 
i.e. there is no difference in the log ratio of hazard function at time t in between the control 
group and the exposed group. 
 
Clustering to obtain robust standard errors: 
 Post-discharge care of an infant can take place at any health care centers in the 
infants surrounding. However, only those encounters that take place at hospitals that utilize 
CERNER EHRs will be recorded in the HF database. Let us assume that there is a mixture 
of health care centers (based on the utilization of CERNER EHR) around an infant’s initial 
treatment center (birthing hospital). Furthermore, that the mixture is random across all the 
different health centers/hospitals where the infant was born/managed. Therefore, the 
probability that an infant will seek care at a hospital or a health center that utilizes CERNER 
EHR can be considered a random effect across the hospitals where the initial care takes 
place. We used the clustered robust standard errors approach, where the observations were 
clustered across the hospitals where the initial care was provided, to account for the 
variability in the probability of access of care at a center that uses CERNER EHR. 
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3.9 Power analysis 
Aim 1: Power analysis for Aim 1 was based on the study conducted by Patrick et 
al. where hospital readmission rates for infants with NOWS was evaluated using New York 
Inpatient Database.36 The study reported that 30-day hospital readmission was 
approximately 3% in infants with NOWS compared to approximately 1.9% in infants with 
uncomplicated term births. Similarly, almost 7.7% of the infants born with NOWS had 
one-year hospital readmissions compared to 4% in infants with uncomplicated term births. 
Additionally, adjusted odds ratio (OR) for 30-day hospital readmissions for infants with 
NOWS was estimated to be 2.49 (95% C.I.: 1.75-3.55) compared to infants who had 
uncomplicated term births. While this study reported that the incidence of NOWS was 
approximately 2 per 1000 births in 2009, we used a recent estimate of 6 per 1,000 births in 
2013105 approximating the time period of our analysis.  
For this calculation, the alpha value was set at 0.05 and sample size to achieve a 
power of 0.8 to 0.85 and was calculated using G*Power software.106 We used a 
dichotomous predictor (presence or absence of NOWS) based on the information available 
for power calculation. 
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Table 8: Power analysis for Aim 1 
Model Power Aim Prevalence 
of NOWSa 
P0 P1 Measure of 
associationb 
Total 
Sample 
size 
Logistic 
regression 
.85 1.A 6 0.03 0.019 OR = 1.6 272,916 
Logistic 
regression 
0.8 1.A 6 0.03 0.019 OR = 1.6 234,313 
Logistic 
regression 
0.85 1.A 6 - - aOR = 2.5 55,052 
Logistic 
regression 
0.8 1.A 6 - - aOR = 2.5 46,396 
Logistic 
regression 
.85 1.B 6 0.077 0.04 OR = 2.0 54,033 
Logistic 
regression 
0.8 1.B 6 0.077 0.04 OR = 2.0 46,048 
a per 1000 births 
b OR = odds ratio, aOR = adjusted odds ratio 
Based on the power analysis for Aim 1, with the conservative estimates (OR=1.6 
and power =0.85) we would need a sample size of approximately 270,000 total births which 
reflects at least 1600 encounters of NOWS based on prevalence rates of 6 per 1000 births 
(Table 8). The constraint in this estimate is primarily the number of births with a diagnosis 
of NOWS in comparison to total birth. Additionally, if we used a stronger effect size of 
OR=2.5 and 80% power, then a total sample size of approximately 46,000 will be sufficient 
for our study. During preliminary analysis we were able to identify approximately 3,000 
encounters with diagnosis of NOWS/NAS. Based on these calculation, we achieved 
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required sample size to be able to detect the effect of diagnosis of NOWS on long-term 
health care utilization. 
Aim 2: Research on the association between severity of NOWS and long-term 
health care utilization is lacking. Hence, we utilized the concept of event per variable 
outlined by Peduzzi et al. to estimate the sample size for Aim 2.107 Based on Peduzzi et 
al.’s work, the sample size for a logistic regression model can be estimated through the 
equation below: 
 N = 10*K / P 
where, N = total sample size 
 K = number of covariates 
 P = proportion of events in the population  
Assuming that we have a minimum of 5 covariates in the model, and that the 
probability of 30-day hospital readmission in infants with NOWS is 0.0336, then the sample 
size required will be approximately 1,666. Similarly, using the rates of hospital readmission 
during the one-year follow-up, which is 0.077, the estimated sample size required would 
be approximately 650. Since our estimated sample size was approximately 3,000, our study 
was powered sufficiently to detect any effect of NOWS severity measures of post-
discharge health care utilization. 
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CHAPTER 4: RESULTS 
In this section we describe the geographic and temporal trends in the incidence of 
NOWS. It is followed by the results for Aim 1 and Aim 2. We conclude the section by 
presenting the results of sensitivity analyses for Aim 1 and Aim 2. 
4.1 Description of sample selection across the study groups: 
 A total of 4,874 encounters related to NOWS (study period Jan 1, 2011 – Sep 30, 
2016) were identified from the HF database. Of this group, 3,526 were selected for 
inclusion in the final study cohort after the application of exclusion criteria and removal of 
duplicates. For the late preterm group, 31,260 infants were identified from the HF database, 
and 24,472 records were included in the study after the application of exclusion criteria 
and removal of duplicates. For the uncomplicated birth group, 433,368 infants were 
initially identified during the same study period from the HF database. Of this group, 
355,875 infants were retained after duplicates were removed and exclusion criteria was 
applied. A random sample of 25% of this group was selected for the final study. Sample 
section/attrition flowchart for the study is presented in Figures 5, 6, and 7.  
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Figure 5: Sample selection flowchart for the NOWS group 
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Figure 6: Sample selection flowchart for the late preterm group 
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Figure 7: Sample selection flowchart for the uncomplicated birth group 
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4.1 Geographic and temporal trends in incidence of NOWS 
The incidence rate of NOWS in infants born into health systems that utilized 
CERNER data systems was approximately 5.9 per 1000 births in the year 2011. There was 
a high degree of variability in the incidence of NOWS across different census divisions. In 
census division 1 (New England) and 3 (East North Central) the incidence rates of NOWS 
was over 10 per 1000 births, whereas in census division 4 (West North Central), 5 (South 
Atlantic), 7 (West South Central), and 9 (Pacific) it was lower than 3 per 1000 births (Table 
9). There was an upward trend in the incidence of NOWS between 2011 and 2016. The 
rates increased from 5.9 per 1000 births in 2011 to 13.1 per 1000 births in 2016 – a 120% 
increase in 5 years. The variability in incidence of NOWS across census divisions persisted, 
with a greater number of census divisions reaching incidence rates of more than 10 per 
1000 births between 2011 and 2016. We also observed a substantial increase in NOWS in 
Census Division 1 where the incidence rate peaked at approximately 50 per 1000 births in 
the year 2014.  
While the incidence of NOWS consistently showed an upward trend, the incidence 
rate of late-preterm birth during the study period remained fairly constant at 63 per 1000 
births until 2015 and then increasing to approximately 72.5 per 1000 births in the year 
2016. This represents a 20% increase between 2011 and 2016.
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Table 9: Incidence rates of NOWS and late preterm per 1000 total live births in infants born into centers that utilized CERNER 
EHR (Years: 2011-2016) 
 
2011 2012 2013 2014 2015 2016 
Census 
division 
NOWS Late 
preterm 
NOWS Late 
preterm 
NOWS Late 
preterm 
NOWS Late 
preterm 
NOWS Late 
preterm 
NOWS Late 
preterm 
1 15.5 70.8 22.3 81.3 32.4 78.0 49.7 57.0 21.8 40.1 17.9 32.7 
2 8.9 51.6 6.1 46.6 4.4 26.2 7.6 30.0 8.5 37.1 20.0 66.7 
3 10.4 76.9 6.6 106.7 5.2 94.2 4.5 98.4 4.8 100.1 6.4 81.4 
4 2.3 34.8 4.4 41.7 9.3 66.7 14.7 76.5 14.1 71.3 3.5 82.1 
5 2.0 58.7 0.9 84.2 1.8 75.5 2.4 78.2 5.0 68.3 18.5 43.6 
6 5.9 81.8 7.9 84.8 5.7 86.9 8.6 73.6 14.1 81.2 18.7 82.6 
7 0.7 72.9 3.9 72.8 3.7 84.8 5.5 74.5 4.9 68.0 6.5 75.7 
8 4.3 45.6 6.3 45.4 15.6 82.5 18.3 77.8 17.0 79.0 16.5 73.1 
9 2.4 65.0 2.8 71.0 1.6 71.8 2.5 67.4 2.2 73.3 6.5 68.4 
Total 5.9 60.6 7.4 65.0 8.0 63.7 11.3 63.0 10.3 64.9 13.1 72.5 
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 Table 10 presents the baseline characteristics of the study groups. Statistical 
significant differences (p<0.05) were observed across sex, race, type of insurance, census 
region of birth, the urban-rural status of the birthing center, and the hospital size (based on 
the number of beds). Compared to the uncomplicated birth group, NOWS and late preterm 
groups had significantly higher proportion of males (52.5% and 53.7%, respectively vs 
50.6% in uncomplicated birth group). Almost 80% of the infants diagnosed with NOWS 
were Caucasian compared to 54.0% in the late preterm group, and 57.0% in the 
uncomplicated birth group. About 69% of the birth-related encounters in the NOWS group 
were covered by Medicaid; 12% were covered by commercial insurance, and the remaining 
by other types of insurance (included self-pay, other non-governmental, military 
dependent, not-reported etc.). In the late preterm group, only 43.8% of birth-related 
encounters were covered by Medicaid, 18.9% by commercial insurance, and the remaining 
by other forms of coverage. Commercial insurance covered 44% of the initial birth-related 
encounters in the uncomplicated birth group, Medicaid covered 34.3%, and 21.5% was 
covered by other forms of coverage. In the NOWS group, 64% of the births were recorded 
in hospitals with greater than 300 beds, 29% in hospitals with 100 to 299 beds, and only 
7.3% in hospitals with less than 100 beds. Late-preterm and uncomplicated births had fairly 
similar distribution to each other in regards to the size of the hospital. Fifty percent of late 
preterm and uncomplicated births were recorded in hospitals with greater than 300 beds, 
37% in hospitals with 100 to 299 beds, and 13% in hospitals with less than 100 beds. 
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Table 10: Description of demographic characteristics and patient care setting by study 
group 
Variable NOWS 
(n=3,526) 
Late 
preterm 
birth 
(n=24,474) 
Uncomplicated 
births* 
(n=88,452) 
p-
value 
Sex     <0.001 
  Male 52.5% 53.7% 50.6%  
  Female 47.5% 46.3% 49.4%  
Race    <0.001 
 Caucasian 79.4% 54.0% 57.0%  
 African American 5.9% 18.8% 14.1%  
 Hispanic 0.8% 2.7% 2.8%  
 Native American 2.7% 2.2% 1.2%  
 Other 11.3% 22.4% 24.9%  
Insurance Type    <0.001 
 Medicaid/Medicaid MC 69.1% 43.8% 34.3%  
 Commercial  11.9% 37.3% 44.4%  
 Other 18.9% 18.9% 21.4%  
Census region    <0.001 
 Midwest 16.9% 25.2% 22.9%  
 Northeast 44.2% 22.6% 33.1%  
 South 23.5% 34.2% 28.1%  
 West 15.4% 18.0% 16.0%  
Rural/Urban Status    <0.001 
 Rural 15.2% 18.2% 17.0%  
 Urban 84.8% 81.8% 83.0%  
Bed size range    <0.001 
 Less than 100 7.4% 13.5% 13.3%  
 100-299 28.5% 36.6% 37.6%  
 Greater than 300 64.2% 50.0% 49.1%  
Year    - 
2011 9.4% 13.9% 15.0%  
2012 11.9% 15.2% 15.2%  
2013 15.3% 17.5% 18.0%  
2014 23.3% 18.8% 19.5%  
2015 20.4% 18.5% 18.4%  
2016 19.3% 16.2% 14.0%  
*Uncomplicated births are 25% sample of the uncomplicated births in each year. 
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There were 782 unique hospital IDs in the HF database. After selection of the cohort 
for our study, we identified 186 unique hospital IDs which represented a total of 116,452 
births that were included in the study. In Table 11, we present the distribution of these 
hospitals based on the U.S. census divisions.  
Table 11: Distribution of hospitals (included in our final analysis) that utilize CERNER 
EHR systems across U.S. census divisions  
Census divisions Hospitals/health centers 
1 (New England) 9 
2 (Mid-Atlantic) 25 
3 (East North Central) 22 
4 (West North Central) 23 
5 (South Atlantic) 11 
6 (East South Central) 37 
7 (West South Central) 17 
8 (Mountain) 24 
9 (Pacific) 18 
Total 186 
  
In Table 12, we describe the characteristics of the primary medical encounter by 
study groups. There was a significant difference in the average LOS across the study groups 
(p<0.001). The average LOS was 14.9 days (SD=11.5) in the NOWS group, 8.6 days 
(SD=8.7) in the late preterm group, and 2.1 days (SD=0.8) in the uncomplicated birth group 
(p<0.001). The median total charges (adjusted to 2016 U.S. dollars) in the NOWS group 
70 
 
was $24,944, $15,970 in the late preterm group, and $3,129 in the uncomplicated birth 
group (p<0.001). 
Respiratory problems were common in both the NOWS and late preterm groups. 
Approximately 20% of the infants in the NOWS group and 34% in the late preterm group 
had respiratory problems (Respiratory distress syndrome, transient tachypnea of newborn, 
other respiratory condition). Major differences between these groups were seen in the 
diagnosis of respiratory distress syndrome (NOWS: 4.7% vs. late preterm: 12.9%, 
p<0.001) and other specified respiratory conditions (NOWS: 7.5% vs. late preterm: 13.8%, 
p<0.001). Respiratory problems in the uncomplicated birth group was less than 3%. In the 
NOWS group, 1.2% of the infants had a diagnostic code for convulsion compared to 0.4% 
in the late preterm group, and 0.1% in the uncomplicated birth group (p<0.001). Other 
commonly present diagnostic codes in the NOWS and the late preterm group were feeding 
difficulties (NOWS: 18.4% vs. late preterm: 22.0%, p<0.001), jaundice (NOWS 35.6% vs. 
late preterm 47.4%, p<0.001), and sepsis (NOWS 4.6% vs. late preterm 7.5%, p<0.001). 
Besides jaundice (uncomplicated birth: 10.9%), these conditions were rare in the 
uncomplicated birth group (less than 2%). 
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Table 12: Description of the primary medical encounter by study groups 
 NOWS 
(n=3,526) 
Late 
preterm 
birth 
(n=24,474) 
Uncomplicated 
births* 
(n=88,452) 
p-
value 
 Mean (SD)  
LOS (days) 14.9 (11.5) 8.6 (8.7) 2.1 (0.8) <0.001 
Total Charges in dollars* 
(median) 
$24,944 $15,970 $3,129 <0.001 
 %  
Gestational age at delivery    <0.001 
33 weeks to less than 37 
weeks 
14.7% 100% 0%  
Any respiratory problems 20.8% 34.0% 2.6% <0.001 
Type of respiratory 
problems 
    
 Respiratory distress 
syndrome 
4.8% 12.9% 0.2%  
 Transient tachypnea of 
newborn 
11.3% 11.8% 1.5%  
 Respiratory condition of 
newborn (unspecified) 
0.8% 1.5% 0.1%  
 Other specified respiratory 
condition 
7.5% 13.8% 1.1%  
Convulsions 1.2% 0.4% 0.1% <0.001 
Feeding difficulties 18.4% 22.0% 1.0% <0.001 
Jaundice 35.6% 47.4% 10.9% <0.001 
Sepsis 4.6% 7.5% 0.4% <0.001 
 
4.2: Results for Specific Aim 1 
Specific Aim 1 examined post-discharge healthcare utilization during the one-year 
follow up period in the NOWS group compared to the late preterm, and uncomplicated 
birth groups. Post-discharge healthcare utilization was measured by emergency department 
visits, hospital readmissions (inpatient stay), and outpatients visits.  
Table 13 shows the rates of post-discharge healthcare utilization during the one-
year follow-up period in the three study groups. The NOWS and late preterm groups 
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showed similar post-discharge health care utilization, such as rates of rehospitalization 
(~4%) and rates of emergency department visits (~7.5%). In comparison, rehospitalization 
and emergency department visits were lower in the uncomplicated birth group (1.6%, and 
6.1% respectively). The mean number of outpatient visit per person was significantly 
higher in the late preterm group (0.047) compared to NOWS (0.037) and uncomplicated 
birth (0.038) groups (p<0.001).  
We observed differences (range: any composite visit: 8.5%-13.2%; any 30-day 
composite visit: 2.1%-6.7%) in the post-discharge health care utilization based on the year 
of discharge (Table 14). Highest rate of post-discharge visits (any composite or any 30-day 
composite visits) were observed in the year 2013. In comparison the rate of post-discharge 
health care utilization in the late preterm and uncomplicated birth groups remained fairly 
constant. 
The association between the study groups and hospital readmissions during the one-
year follow-up period is shown in Table 15. In the unadjusted model, we observed 
significantly higher odds of hospital readmission in the NOWS group (OR: 2.5, 95% C.I.: 
2.0-3.3) compared to controls (uncomplicated birth). In model 2 (adjusted for sex, race, 
insurance type, urban-rural status, census region, hospital size and year of discharge), the 
results still showed a significant association between NOWS and hospital readmission (OR 
2.0, 95% C.I.: 1.4-2.7) when compared to uncomplicated birth group. In model 3 
(additional adjustment for respiratory conditions, feeding problems, jaundice, sepsis, and 
convulsions) the odds of rehospitalization in the follow-up period in the NOWS group was 
1.7 times the odds in the uncomplicated birth group (95%CI: 1.4-1.9). Similarly, across all 
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the models, infants who had late preterm births showed higher odds of rehospitalization 
during the one-year follow-up period when compared to the uncomplicated birth group. 
There was a significant association between NOWS and 30-day rehospitalization 
(OR: 2.7, 95% C.I.: 1.9-3.8). The association persisted after the adjustment for 
demographic and hospital-related factors in model 2 (OR: 2.1, 95% C.I.: 1.4-3.2) and 
medical conditions in model 3 (OR: 1.9, 95% C.I.: 1.3-2.6). Similarly, across all the 
models, infants who had late preterm births also showed higher odds of 30-day 
rehospitalization compared to uncomplicated birth group. 
In the sub-group analysis, we compared the rates of rehospitalization in the NOWS 
group to the late preterm group. After adjustment of demographics and medical conditions, 
the odds of any rehospitalization was lower in the NOWS group (OR: 0.8, 95% C.I.: 0.6-
0.98) compared to the late preterm group. However, there was no difference in 30-day 
rehospitalization across these groups (NOWS vs. late preterm group). 
Table 16 describes the association between emergency department visits and study 
groups during the one-year follow-up period. In the unadjusted analysis, we observed that 
infants in the NOWS group had higher odds of emergency department visits compared to 
the uncomplicated birth group in the one-year follow-up period (OR: 1.5, 95% C.I.: 1.1-
1.9). The results were not statistically significant after adjustment of demographic factors 
in model 2, and after the addition of medical conditions in model 3. In the unadjusted 
model, the NOWS group had higher odds of 30-day emergency department visits compared 
to the uncomplicated birth group (OR: 1.5, 95% C.I.: 1.2-1.9). After adjustments in model 
2 and 3, the association was marginally significant (Model 3, OR: 1.3, 95% C.I.: 1.0-1.6). 
However, compared to the uncomplicated birth group, late preterm group had significantly 
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higher odds of any emergency department visit and 30-day emergency department visit in 
all the unadjusted and adjusted models. In the sub-group analysis, we observed no 
difference in the rates of any emergency department visits (one-year period) or 30-day 
emergency department visits across all the unadjusted and adjusted logistic regression 
models between the NOWS group and the late preterm group. 
Table 17 describes the differences in composite healthcare utilization (i.e., any 
emergency department visit or rehospitalization), during the one-year follow-up period 
between the study groups. In the unadjusted analysis, there were higher odds of composite 
healthcare utilization in the NOWS group (OR: 1.5, 95% C.I.: 1.4-1.7) compared to the 
uncomplicated birth group. However, after adjustments, these associations were not 
statistically significant.  
We found higher odds of 30-day composite health care utilization in the NOWS 
group compared to the uncomplicated birth group across all unadjusted and adjusted 
logistic regression models. The unadjusted model showed that the odds of composite 
healthcare utilization in the NOWS group was 1.9 times the odds in the uncomplicated 
birth group (95% C.I.: 1.6-2.2). After adjusting for demographics and hospital 
characteristics in model 2 the odds ratio was 1.5 (95% C.I.: 1.3-1.8). In model 3, the odds 
ratio was 1.4 (95% C.I.: 1.2-1.6).  
We found similar association between late preterm birth and composite measures 
of healthcare utilization. The late preterm group had significantly higher odds of a hospital 
or emergency room visit, or any 30-day composite visit, compared to the uncomplicated 
birth group across all unadjusted and adjusted models. In the sub-group analysis, NOWS 
group had lower odds of any composite visit, compared to the late preterm group, after 
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adjustment of demographics and medical characteristics (Model 3, OR: 0.8, 95% C.I.: 0.6-
0.98). However, there was no difference in any 30-day composite health care utilization 
across the two groups.  
The results of analysis of differences in post-discharge outpatient visits across the 
study groups is presented in Table 18. In the unadjusted and adjusted logistic regression 
models, there were no differences in the odds of outpatient visit across the study groups. 
Similarly, in the sub-group analysis, there were no differences in post-discharge outpatient 
visit between the NOWS group and the late preterm group. 
Model metrics-AUROC for logistic regression models 
The unadjusted logistic regression model with the study group as the predictor had 
an AUROC of 60% or lower across the outcome measures evaluated in the study. Addition 
of infant demographic covariates in model 2 showed considerable improvement in AUROC 
(from 60% to approximately 68%). However, addition of other medical condition related 
covariates in model 3 did not produce major improvements in the AUROC (approximate 
improvement in AUROC 1.5%) These changes in AUROC showed that adding covariates 
related to medical condition over the demographic characteristics did not provide 
additional information in predicting post-discharge health care utilization. This is likely 
because these conditions were common in the late preterm and NOWS group possibly 
leading to more collinearity rather than explaining the variability of the outcomes.  
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Table 13: Post-discharge healthcare utilization by study groups 
Variable NOWS 
(n=3,526) 
Late 
preterm 
birth 
(n=24,474) 
Uncomplicated 
births 
(n=88,452) 
p-
value 
Rehospitalization     
 Mean rehospitalization 0.042 0.049 0.0166 <0.001 
 Any rehospitalization  3.8% 4.3% 1.6% <0.001 
 Any 30-day 
rehospitalization 
2.4% 2.9% 0.9% <0.001 
Emergency Department      
 Mean emergency 
department visit  
0.114 0.114 0.86 <0.001 
 Any emergency 
department visit 
7.5% 7.6% 6.1% <0.001 
 Any 30-day emergency 
department visit 
2.0% 1.8% 1.6% <0.001 
Any (Rehospitalization 
or Emergency 
Department) 
    
 Total mean visits 
(Rehospitalization and 
Emergency Department)  
0.156 0.163 0.102 <0.001 
 Any visit 
(Rehospitalization and 
Emergency Department) 
10.4% 11.1% 7.3% <0.001 
 Any 30-day visit 
(Rehospitalization and 
Emergency Department) 
4.3% 4.5% 2.4% <0.001 
Outpatient visit     
 Mean outpatient visit  0.371 0.470 0.376. <0.001 
 Any outpatient  12.4% 16.2% 14.9% <0.001 
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Table 14: Yearly variation in post-discharge health care utilization (Composite measures) 
across study groups 
Any e visit 
Year NOWS 
(n=3,526) 
Late preterm 
birth 
(n=24,474) 
Uncomplicated 
births 
(n=88,452) 
2011 8.5% 10.7% 7.3% 
2012 12.4% 12.1% 8.4% 
2013 13.2% 11.4% 7.6% 
2014 8.5% 10.1% 7.7% 
2015 10.8% 11.6% 7.0% 
2016 9.7% 10.3% 5.5% 
    
Any 30-day visit 
Year  
2011 2.1% 3.9% 1.9% 
2012 5.7% 5.1% 2.4% 
2013 6.7% 4.7% 2.5% 
2014 3.0% 3.9% 2.5% 
2015 3.3% 4.8% 2.4% 
2016 4.9% 4.8% 2.9% 
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Table 15: Logistic regression model for rehospitalization during one-year follow-up period 
 Model 1 Model 2 Model 3 
 Odds Ratio (95% C.I.) 
Any rehospitalization 
Uncomplicated births 
(Ref) vs. NOWS 
2.5 (2.0-3.3) 2.0 (1.4-2.7) 1.7 (1.3-2.2) 
Uncomplicated births 
(Ref) vs. Late preterm 
births 
2.9 (2.3-3.6) 2.7 (2.2-3.3) 2.2 (1.8-2.7) 
AUROC 61.5% 68.5% 69.0% 
Sub-group analysis 
Late preterm births 
(Ref) vs. NOWS 
0.9 (0.7-1.1) 0.7 (0.6-0.9) 0.8 (0.6-0.98) 
AUROC 50.7% 62.4% 63.3% 
    
30-day rehospitalization 
Uncomplicated births 
(Ref) vs. NOWS 
2.7 (1.9-3.8) 2.1 (1.4-3.2) 1.9 (1.3-2.6) 
Uncomplicated births 
(Ref) vs. Late preterm 
births 
3.3 (2.6-4.3) 3.1 (2.4-4.0) 2.6 (2.0-3.3) 
AUROC 63.0% 69.0% 69.6% 
Sub-group analysis 
Late preterm births 
(Ref) vs. NOWS 
0.8 (0.6-1.0) 0.7 (0.5-1.0) 0.7 (0.5-1.1) 
AUROC 51.1% 61.9% 62.2% 
Ref: Reference 
AUROC: Area under the receiver operating characteristic curve (for the logistic regression 
models) 
Model 1: Unadjusted model 
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division, 
hospital size, year of discharge 
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and 
convulsions 
 
  
79 
 
Table 16: Logistic regression model for emergency department visits during one-year 
follow-up period 
 Model 1 Model 2 Model 3 
 Odds Ratio (95% C.I.) 
Any emergency department visit 
Uncomplicated births 
(Ref) vs. NOWS 
1.5 (1.1-1.9) 1.1 (0.9-1.3) 1.0 (0.8-1.2) 
Uncomplicated births 
(Ref) vs. Late preterm 
births 
1.6 (1.4-1.9) 1.4 (1.3-1.6) 1.2 (1.2 -1.5) 
AUROC 52.3% 67.7% 67.7% 
Sub-group analysis 
Late preterm births 
(Ref) vs. NOWS 
1.0 (0.7-1.4) 0.8 (0.7-1.1) 0.8 (0.6-1.1) 
AUROC 50.1% 65.0% 65.0% 
30-day emergency department visit 
Uncomplicated births 
(Ref) vs. NOWS 
1.8 (1.7-2.3) 1.4 (1.1-1.8) 1.3 (1.0-1.6) 
Uncomplicated births 
(Ref) vs. Late preterm 
births 
1.9 (1.6-2.3) 1.7 (1.4-2.0) 1.6 (1.3-1.8) 
AUROC 51.2% 66.5% 66.5% 
Sub-group analysis 
Late preterm births 
(Ref) vs. NOWS 
1.2 (0.8-1.6) 1.1 (0.9-1.5) 1.1 (0.9-1.5) 
AUROC 50.9% 64.9% 65.1% 
Ref: Reference 
AUROC: Area under the receiver operating characteristic curve (for the logistic regression 
models) 
Model 1: Unadjusted model 
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division, 
hospital size, year of discharge 
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and 
convulsions 
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Table 17: Logistic regression model for any emergency department visit or 
rehospitalization during one-year follow-up period 
 Model 1 Model 2 Model 3 
 Odds Ratio (95% C.I.) 
Any visit (emergency department or rehospitalization) 
Uncomplicated births 
(Ref) vs. NOWS 
1.5 (1.4-1.7) 1.1 (1.0-1.3) 1.1 (0.9-1.2) 
Uncomplicated births 
(Ref) vs. Late preterm 
births 
1.6 (1.6-1.7) 1.5 (1.4-1.6) 1.4 (1.3-1.4) 
AUROC 54.6% 66.4% 66.5% 
Sub-group analysis 
Late preterm births 
(Ref) vs. NOWS 
0.9 (0.7-1.2) 0.8 (0.6-0.96) 0.8 (0.6-0.98) 
AUROC 50.4% 62.7% 62.9% 
Any 30-day visit (emergency department or rehospitalization) 
Uncomplicated births 
(Ref) vs. NOWS 
1.9 (1.6-2.2) 1.5 (1.3-1.8) 1.4 (1.2-1.6) 
Uncomplicated births 
(Ref) vs. Late preterm 
births 
2.0 (1.9-2.2) 1.9 (1.7-2.0) 1.7 (1.5-1.8) 
AUROC 56.7% 64.9% 65.1% 
Sub-group analysis 
Late preterm births 
(Ref) vs. NOWS 
0.9 (0.7-1.2) 0.9 (0.7-1.1) 0.9 (0.7-1.2) 
AUROC 50.4% 59.9% 60.0% 
Ref: Reference 
AUROC: Area under the receiver operating characteristic curve (for the logistic regression 
models) 
Model 1: Unadjusted model 
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division, 
hospital size, year of discharge 
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and 
convulsions 
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Table 18: Logistic regression model for any outpatient visit during one-year follow-up 
period 
 Model 1 Model 2 Model 3 
 Odds Ratio (95% C.I.) 
Uncomplicated births 
(Ref) vs. NOWS 
0.8 (0.4-1.5) 0.9 (0.6-1.5) 0.9 (0.6-1.4) 
Uncomplicated births 
(Ref) vs. Late preterm 
births 
1.1 (0.9-1.4) 1.0 (0.8-1.2) 1.0 (0.9-1.2) 
AUROC 51.2% 69.7% 69.8% 
Sub-group analysis 
Late preterm births 
(Ref) vs. NOWS 
0.7 (0.4-1.2) 0.8 (0.6-1.2) 0.8 (0.6-1.2) 
AUROC 51.6% 67.9% 68.2% 
Ref: Reference 
AUROC: Area under the receiver operating characteristic curve (for the logistic regression 
models) 
Model 1: Unadjusted model 
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division, 
hospital size, year of discharge 
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and 
convulsions 
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Tables 19 and 20 present the comparison of the incidence rates of post-discharge 
health care utilization among the study groups, using Poisson and Zero-inflated Poisson 
regression models. The incidence rates of any composite visit and rehospitalization were 
significantly higher in the NOWS group compared to the uncomplicated birth group across 
all unadjusted and adjusted models (any composite visit Model 3: IRR: 1.4, 95% C.I.: 1.2-
1.6 and rehospitalization, Model 3: IRR: 2.1, 95% C.I.: 1.6-2.7). For any emergency 
department visit, the association was marginally significant across all three statistical 
models (Model 3, IRR: 1.3, 95% C.I.: 1.02-1.6) between NOWS group and uncomplicated 
birth group. No differences in the rates of outpatient visits were observed across the study 
groups.  
To account for the high number of zero values in the counts of healthcare utilization 
visits (no use), we used the Zero-inflated Poisson regression model as a robustness check 
for our previous analysis. The incidence rate of any composite visit in the NOWS group 
was not significantly different than that in the uncomplicated birth group (Model 3, IRR: 
1.1, 95% C.I.: 0.95-1.3). However, the incidence rate of rehospitalization in the NOWS 
group was statistically significant (Model 3, IRR: 1.8, 95% C.I.: 1.4-2.3) when compared 
to the uncomplicated birth group. We did not observe significant differences in the rates of 
emergency department visit or outpatient visit in the NOWS group compared to the 
uncomplicated birth groups.  
In the sub-group analysis (Table 20), there were no differences in any composite 
visit, emergency department or outpatient visit, in the NOWS group vs. the late preterm 
group. The rates of rehospitalization, however, were significantly lower in the NOWS 
group (Model 3, IRR: 0.8, 95% C.I.: 0.6-0.9) compared to the late preterm group. 
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Model metrics-AIC/N for Poisson regression models 
 The unadjusted Poisson regression model with the study group as the predictor and 
any composite visit as outcome had an AIC/N value of 0.798 (lower scores denote better 
fit). Addition of covariates, such as sex, race, insurance type, urban-rural status, year, 
hospital id, and census division, in model 2 showed improvement in AIC to 0.777. 
However, addition of other medical condition related covariate in model 3 did not produce 
any changes in AIC/N values. Similarly, the AIC/N values for any rehospitalization 
improved to 0.226 from 0.224 after addition of demographic and hospital characteristics 
related covariates. There was no improvement in AIC/N in Model 3. The results for the 
Poisson model for emergency department visits and outpatient visits also showed 
consistent pattern of improvement in model 2 after addition of demographics and hospital 
characteristics but no change with the addition of other covariates in Model 3. 
Similarly, in the Zero-inflated Poisson regression models, consistent improvement 
in the model fit was observed after the addition of demographic and hospital related 
covariates in Model 2 over Model 1. There was limited or almost no improvement in model 
fit in model 3.  
  These changes in the AIC/N showed that medical covariates (Model 3) did not add 
additional information beyond what was provided by demographic characteristics in model 
2. As explained previously, this is likely because these conditions were most common in 
the late preterm and NOWS group possibly leading to more collinearity rather than 
explaining the variability of the outcomes. 
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Table 19: Poisson and Zero-inflated Poisson model for post-discharge health care 
utilization by study groups during one-year follow-up period 
 Any visit Rehospitalization Emergency 
department 
Outpatient 
visits 
 IRR (95% C.I.) 
Poisson model 
Model 1  - - - - 
Uncomplicated 
births (Ref) vs. 
NOWS 
1.5 (1.2-2.0) 2.5 (2.0-3.2) 1.3 (0.9-1.9) 1.0 (0.5-2.0) 
Uncomplicated 
births (Ref) vs. Late 
preterm births 
1.6 (1.4-1.9) 3.0 (2.3-3.7) 1.3 (1.1-1.6) 1.2 (1.03-
1.5) 
AIC/N 0.798 0.226 0.679 2.188 
Model 2 - - - - 
Uncomplicated 
births (Ref) vs. 
NOWS 
1.5 (1.2-1.8) 2.4 (1.8-3.1) 1.3 (1.04-
1.6) 
1.0 (0.5-2.0) 
Uncomplicated 
births (Ref) vs. Late 
preterm births 
1.5 (1.3-1.7) 2.9 (2.3-3.6) 1.2 (1.1-1.4) 1.1 (0.9-1.4) 
AIC/N 0.777 0.224 0.658 1.989 
Model 3 - - - - 
Uncomplicated 
births (Ref) vs. 
NOWS 
1.4 (1.2-1.6) 2.1 (1.6-2.7) 1.3 (1.02-
1.6) 
1.0 (0.5-2.0) 
Uncomplicated 
births (Ref) vs. Late 
preterm births 
1.4 (1.2-1.6) 2.4 (1.9-3.0) 1.2 (1.0-1.3) 1.1 (0.9-1.3) 
AIC/N 0.777 0.224 0.658 1.987 
Zero inflated Poisson model 
Model 1 - - - -- 
Uncomplicated 
births (Ref) vs. 
NOWS 
1.2 (0.9-1.5) 2.2 (1.8-2.6) 1.0 (0.8-1.4) 1.0 (0.5-2.1) 
Uncomplicated 
births (Ref) vs. Late 
preterm births 
1.3 (1.2-1.5) 2.8 (2.2-3.5) 1.2 (1.1-1.3) 1.2 (1.03-
1.5) 
AIC/N 0.702 0.220 0.583 1.354 
Model 2 - - - - 
Uncomplicated 
births (Ref) vs. 
NOWS 
1.2 (1.1-1.3) 2.0 (1.6-2.6) 1.0 (0.8-1.3) 1.1 (0.7-1.7) 
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Uncomplicated 
births (Ref) vs. Late 
preterm births 
1.4 (1.3-1.4) 2.8 (2.2-3.4) 1.2 (1.1-1.3) 1.2 (1.0-1.4) 
AIC/N 0.693 0.219 0.576 1.303 
Model 3 - - - - 
Uncomplicated 
births (Ref) vs. 
NOWS 
1.1 (0.95-
1.3) 
1.8 (1.4-2.3) 1.0 (0.8-1.3) 1.1 (0.7-1.6) 
Uncomplicated 
births (Ref) vs. Late 
preterm births 
1.3 (1.2-1.4) 2.4 (1.9-2.9) 1.2 (1.0-1.3) 1.1 (1.0-1.3) 
AIC/N 0.693 0.218 0.575 1.303 
IRR: Incidence rate ratio 
AIC/N: Akaike information coefficient/sample size 
Model 1: Unadjusted model 
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division, 
hospital size, year of discharge 
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and 
convulsions 
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Table 20: Sub-group analysis: Zero-Inflated Poisson model for post-discharge health care 
utilization during one-year follow-up period 
 Any visit Rehospitalization Emergency 
department 
Outpatient 
visits 
 IRR (95% C.I.) 
Zero-inflated Poisson model 
Model 1 - - - -- 
Late preterm 
births (Ref) vs. 
NOWS 
0.9 (0.7-1.2) 0.8 (0.6-0.97) 0.9 (0.7-1.2) 0.8 (0.4-1.5) 
AIC/N 0.904 0.387 0.684 1.438 
Model 2 - - - - 
Late preterm 
births (Ref) vs. 
NOWS 
0.9 (0.7-1.1) 0.7 (0.6-0.9) 0.9 (0.7-1.1) 0.8 (0.6-1.2) 
AIC/N 0.893 0.383 0.675 1.390 
Model 3 - - - - 
Late preterm 
births (Ref) vs. 
NOWS 
0.9 (0.7-1.1) 0.8 (0.6-0.9) 0.9 (0.7-1.1) 0.8 (0.6-1.1) 
AIC/N 0.893 0.382 0.675 1.389 
IRR: Incidence rate ratio 
AIC/N: Akaike information coefficient/sample size 
Model 1: Unadjusted model 
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division, 
hospital size, year of discharge 
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and 
convulsions 
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Mean time to the first emergency visit in the NOWS group was 153 (SD: 112) days 
as opposed to 154 (SD: 113) days in the late preterm group and 157 (SD: 116) days in the 
uncomplicated birth group (p=0.53). The mean time to the first rehospitalization was 71.9 
(SD: 105) days in the NOWS group, 52 (SD: 86) days in the late preterm group, and 63.3 
(SD: 89.1) days in the uncomplicated birth group (p<0.05). These means reflect the average 
number of days until the first event for infants who had the specific event (emergency 
department visit or rehospitalization). The Kaplan-Meier curves for rehospitalization and 
emergency department visits are shown in Figure 8. There were significant differences in 
the time to event for both emergency department visit and rehospitalization across the study 
groups based on the log-rank test of equality of survival functions (p<0.001).  
Using Cox proportional-hazards regression, we estimated the hazard ratios (HR) of 
outcomes across the study groups (i. emergency visit and ii. rehospitalization, Table 21). 
There were no significant differences in the hazard ratios for emergency department visits 
in the NOWS group compared to the uncomplicated birth group across all unadjusted and 
adjusted Cox proportional-hazards regression models. In the sub-group analysis, 
comparing NOWS group to the late preterm group, we did not observe any significant 
difference in the hazard ratio for emergency department visits. 
The hazard rate for rehospitalization was significantly higher in the NOWS group 
compared to the uncomplicated birth group in the unadjusted model (HR: 2.0, 95% C.I.: 
1.6-2.5). The association remained significant even after adjustment for demographic 
characteristics (HR: 1.5, 95% C.I.: 1.2-1.9), and medical conditions (HR: 1.4, 95% C.I.: 
1.1-1.8). In the sub-group analysis, the hazard rate for rehospitalization in the NOWS group 
was not statistically significant when compared to the late preterm group in the unadjusted 
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analysis. However, after adjusting for other confounders we observed that the HR for 
rehospitalization was lower in the NOWS group compared to the late preterm group (Model 
3, HR: 0.7, 95% C.I.: 0.6-0.8).   
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Table 21: Survival analysis: Time to first incidence of post-discharge health care utilization 
across study groups during one-year follow-up period 
 Emergency visit Rehospitalization 
Cox proportional-hazards 
regression 
HR (95% C.I.) HR (95% C.I.) 
Model 1   
Uncomplicated births (Ref) vs. 
NOWS 
1.2 (0.9-1.7) 2.0 (1.6-2.5) 
Uncomplicated births (Ref) vs. 
Late preterm births 
1.3 (1.1-1.5) 2.4 (2.0-2.9) 
Model 2   
Uncomplicated births (Ref) vs. 
NOWS 
0.9 (0.7-1.2) 1.5 (1.2-1.9) 
Uncomplicated births (Ref) vs. 
Late preterm births 
1.1 (1.0-1.3) 2.2 (1.9-2.7) 
Model 3   
Uncomplicated births (Ref) vs. 
NOWS 
0.9 (0.7-1.1) 1.4 (1.1-1.8) 
Uncomplicated births (Ref) vs. 
Late preterm births 
1.1 (0.9-1.2) 2.0 (1.7-2.4) 
Sub-group analysis* 
Model 1   
Late preterm births (Ref) vs. 
NOWS 
1.0 (0.7-1.4) 0.8 (0.7-1.1) 
Model 2   
Late preterm births (Ref) vs. 
NOWS 
0.8 (0.7-1.1) 0.7 (0.6-0.8) 
Model 3   
Late preterm births (Ref) vs. 
NOWS 
0.8 (0.7-1.1) 0.7 (0.6-0.8) 
Model 1: Unadjusted model 
Model 2: Adjusted for LOS, sex, race, insurance type, urban rural status, census division, 
hospital size, year of discharge 
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and 
convulsions 
*Models 2 and 3 also include initial LOS for the sub-group analysis 
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Figure 8: Kaplan-Meier survival curves by study groups. A: Emergency department visit B. Rehospitalization 
 
  
91 
 
4.3: Results for Specific Aim 2 
Table 22 describes the baseline characteristics of the NOWS group divided across 
infants who received pharmacologic treatment (received methadone, morphine, tincture of 
opium and/or phenobarbital, henceforth termed “Treated-For-NOWS”) and infants who 
did not receive pharmacological treatment for NOWS (Not-Treated-For-NOWS). This sub-
group (Treated-For-NOWS) accounted for 34% of the infants in the NOWS group. There 
were no significant differences between infants who were Treated-For-NOWS and those 
who were Not-Treated-For-NOWS with respect to sex, race, or urban-rural status (p>0.05). 
Statistically significant differences were present between these two groups with respect to 
type of insurance, census region, and hospital size (p<0.05). 
The differences in characteristics of the primary medical encounter by 
pharmacological treatment of NOWS is presented in Table 23. Infants in the Treated-For-
NOWS group had significantly longer LOS in the hospital following birth, compared to 
Not-Treated-for-NOWS group (21.9 days vs. 12.2 days, p<0.001). Additionally, the 
median cost for those in the Treated-For-NOWS group was approximately $52,000, 
compared to $10,000 in the Not-Treated-For-NOWS group. 
Overall, a larger proportion of infants in the Treated-For-NOWS group had medical 
conditions, such as respiratory problems, convulsions, feeding difficulties, and sepsis (all 
p-values <0.001). Observed respiratory problems within this group included respiratory 
distress syndrome, transient tachypnea of newborn, and other unspecified respiratory 
condition. A high proportion of infants in both groups had jaundice (35%, p=0.74). 
Medications received during the pharmacological treatment are presented in Table 
24. Among, infants who were diagnosed with NOWS a majority received either morphine 
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or methadone (31%) followed by antibiotics (16%) and phenobarbital (6%). Morphine was 
the most common medication of choice for pharmacologic management treatment of 
NOWS (72.5%). Infants in the Treated-For-NOWS group were also administered 
benzodiazepines and antibiotics at significantly higher rates than those in the Not-Treated-
For-NOWS group (p<0.001). 
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Table 22: Description of demographic characteristics and patient care setting in infants 
diagnosed with now based on pharmacologic treatment 
 NOWS 
(n=3,526) 
Treated-For-
NOWS 
(n=1,203) 
Not-Treated-
For-NOWS 
(n=2,323) 
p-
value 
Sex    0.170 
  Male 52.5% 54.1% 51.7%  
  Female 47.5% 45.9% 48.3%  
Race    0.099 
  Caucasian 79.4% 78.5% 79.9%  
  African American 5.9% 4.9% 6.4%  
  Hispanic 0.8% 0.8% 0.8%  
  Native American 2.7% 3.1% 2.5%  
  Other 11.3% 12.8% 10.5%  
Insurance type    0.001 
  Medicaid/ Medicaid MC 69.1% 73.2% 67.0%  
  Commercial 11.9% 9.8% 13.0%  
  Other 18.9% 17.0% 19.9%  
Census region    <0.001 
  Midwest 16.9% 10.4% 20.3%  
  Northeast 44.2% 42.0% 45.3%  
  South 23.5% 25.0% 22.8%  
  West 15.4% 22.6% 11.6%  
Urban rural status    0.683 
  Urban 84.8% 84.5% 85.0%  
  Rural 15.2% 15.5% 15.0%  
Hospital size (number of 
beds) 
   <0.001 
  Less than 100 7.4% 4.0% 9.2%  
  100-299 28.4% 31.3% 27.0%  
  Greater than 300 64.2% 64.8% 63.9%  
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Table 23: Description of primary medical encounter by status of pharmacologic treatment 
for NOWS 
Variable NOWS 
(n=3,526) 
Treated-For-
NOWS 
(n=1,203) 
Not-Treated-
For-NOWS 
(n=2,323) 
p-
value 
 Mean (SD)  
LOS (days) 14.9 (11.5) 19 (11.6) 11.4 (9.7) <0.001 
Total Charges in dollars* 
(median) 
$24,944 $60,355 $11,989 <0.001 
 %  
Gestational age at delivery    0.303 
  33 weeks to less than 37 
weeks 
14.7% 15.5% 14.3%  
Any respiratory problems 20.8% 27.5% 17.4% <0.001 
Type of respiratory 
problems 
    
  Respiratory distress 
syndrome 
4.8% 7.5% 3.4% <0.001 
   Transient tachypnea of 
newborn 
11.3% 13.8% 9.9% <0.001 
   Respiratory condition of 
newborn (unspecified) 
0.8% 1.2% 0.7% 0.106 
   Other specified respiratory 
condition 
7.5% 10.2% 6.1% <0.001 
Convulsions 1.2% 1.9% 0.8% 0.005 
Feeding difficulties 18.4% 26.2% 14.4% <0.001 
Jaundice 35.6% 36.0% 35.4% 0.740 
Sepsis 4.6% 6.9% 3.4%  
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Table 24: Description of medication received during primary medical encounter by status 
of pharmacologic treatment for NOWS 
 NOWS 
(n=3,526) 
Treated-For-
NOWS 
(n=1,203) 
Not-Treated-
For-NOWS 
(n=2,323) 
p-
value 
Received morphine 24.7% 72.5% -  
Received methadone 7.9% 23.3% -  
Received opium 0.2% 0.7% -  
Received morphine or 
methadone 
31.2% 91.4% -  
Received phenobarbital 6.4% 18.7% -  
Received benzodiazepines 1.5% 3.2% 0.6% <0.001 
Received antibiotics 16.3% 25.6% 11.4% <0.001 
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4.3.1 Analysis of the association between pharmacological treatment of NOWS and post-
discharge health care utilization 
A wide variability in post-discharge healthcare utilization (Table 25) across infants 
who received/did not receive pharmacological treatment for NOWS was found. Any 
emergency department visit (10.1% vs. 6.2%, p<0.001) and the mean number of emergency 
department visits (0.164 vs. 0.089, p<0.001) in the one-year follow-up period were 
significantly higher in Treated-For-NOWS group when compared to Not-Treated-For-
NOWS group. Treated-For-NOWS group also had higher any composite visit (13.0% vs. 
9.0%, p<0.001) and had higher mean number of composite visits (0.211 vs. 0.129, 
p<0.001) compared to Not-Treated-For-NOWS group. We did not find any significant 
differences in the mean number of rehospitalization events or any post-discharge 
rehospitalization based on their pharmacological treatment status. Furthermore, we did not 
observe any significant differences in the rates of outpatients visits based on the 
pharmacological treatment status of the infant.  
4.3.2 Analysis of the association between NOWS related severity measures and post-
discharge healthcare utilization  
In the unadjusted logistic regression model (Table 26), medical conditions, such as 
respiratory conditions (OR: 1.8, 95% C.I.: 1.1-2.9), feeding difficulties (OR: 1.6, 95% C.I.: 
1.1-2.5), and receiving antibiotics (OR: 1.4, 95% C.I.: 1.1-1.9) were associated with higher 
odds of rehospitalization. We did not observe any associations between the 
pharmacological treatment, LOS, prematurity, medications (phenobarbital, barbiturates), 
sepsis and rehospitalization. In the adjusted model, these associations were not statistically 
significant either. In both the unadjusted and adjusted models, there was no association 
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between odds of any 30-day rehospitalization and medication received, LOS, prematurity, 
or medical conditions diagnosed at initial hospital stay.  
A significant association between pharmacologic treatment for NOWS and 
emergency department visit was observed (OR: 1.6, 95% C.I.: 1.02-2.8; Table 27). 
However, in the adjusted models, the association was not statistically significant (OR: 1.4, 
95% C.I.: 0.9-2.1). Infants who had a respiratory condition at birth were found to have 
higher odds of 30-day emergency department visit. However, the association was not 
significant after controlling for other factors. In the unadjusted logistic regression model, 
we did not observe any effect of LOS, prematurity, medications (phenobarbital, 
barbiturates, and antibiotics), and medical conditions on any emergency department visit. 
Receiving benzodiazepines (OR: 2.1, 95% C.I.: 1.1-3.8) and having respiratory 
conditions (OR: 1.5, 95% C.I.: 1.1-2.0) were associated with higher odds of any composite 
visit during the post-discharge follow-up period (Table 28). Pharmacologic treatment of 
NOWS, LOS, feeding difficulties, and jaundice showed marginal association with any 
composite visits. In the full model, these associations were not statistically significant. 
Respiratory conditions and LOS were associated with higher odds of any 30-day visit. 
After adjustment, marginal statistical significances was observed for both of these factors. 
We did not observe any statistically significant association between majority of the 
NOWS severity measures and outpatient visits (Table 29). However, in the adjusted model, 
receiving benzodiazepines was found to be associated with higher odds of outpatient visits 
(OR: 2.6, 95% C.I.: 1.2-5.2) 
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Table 25: Description of post-discharge healthcare utilization in infants diagnosed with 
NOWS by status of pharmacological treatment for NOWS 
Variable NOWS 
(n=3,526) 
Treated-For-
NOWS 
(n=1,203) 
Not-Treated-
For-NOWS 
(n=2,323) 
p-
value 
Rehospitalization     
Mean rehospitalization  0.042 (0.22) 0.047 (0.24) 0.040 (0.21) 0.322 
Any rehospitalization  3.8% 4.2% 3.7% 0.466 
Any 30-day 
rehospitalization 
2.4% 2.2% 2.5% 0.536 
Emergency Department      
Mean emergency 
department  
0.114 (0.48) 0.164 (0.60) 0.089 (0.39) <0.001 
Any emergency 
department visit 
7.5% 10.1% 6.2% <0.001 
Any 30-day emergency 
department visit 
2.0% 2.5% 1.8% 0.172 
Any (Rehospitalization 
or Emergency 
Department) 
    
Total mean visits 
(Rehospitalization and 
Emergency Department)  
0.157 (0.56) 0.211 (0.70) 0.129 (0.47) <0.001 
Any visit 
(Rehospitalization and 
Emergency Department) 
10.4% 13.0% 9.0% <0.001 
Any 30-day visit 
(Rehospitalization and 
Emergency Department) 
4.3% 4.5% 4.1% 0.619 
Outpatient visit     
Mean outpatient visit per 
1000 
0.371 (1.45) 0.40 (1.56) 0.36 (1.38) 0.372 
Any outpatient  12.4% 12.2% 12.5% 0.821 
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Table 26: Logistic regression model: Examination of factors affecting rehospitalization in 
infants with NOWS 
 Any rehospitalization 30-day rehospitalization 
 Unadjusted Adjusted* Unadjusted Adjusted* 
 OR (95% 
C.I.) 
OR (95% 
C.I.) 
OR (95% 
C.I.) 
OR (95% 
C.I.) 
Treated-For-NOWS 1.1 (0.7-1.9) 1.0 (0.6-1.7) 0.9 (0.4-1.4) 0.8 (0.4-1.5) 
LOS 1.0 (0.99-
1.02) 
1.0 (0.98-
1.0) 
1.0 (0.99-
1.02) 
1.0 (0.97-
1.0) 
Received phenobarbital 0.4 (0.2-1.2) - 0.4 (1.0-1.3) - 
Received benzodiazepine 2.1 (0.9-5.2) 2.3 (0.8-6.6) 2.6 (0.9-7.7) 2.9 (0.8-
11.2) 
Any respiratory condition 1.8 (1.1-2.9) 1.5 (0.8-2.5) 1.7 (0.9-3.2) 1.6 (.0.8-3.2) 
Feeding difficulties 1.6 (1.1-2.5) 1.5 (1.0-2.2) 1.6 (0.9-2.8) 1.2 (0.9-1.6) 
Prematurity 1.1 (0.7-1.6) 0.8 (0.5-1.2) 1.0 (0.6-1.6) 0.7 (0.4-1.3) 
Received antibiotic 1.4 (1.1-1.9) 1.2 (0.8-1.7) 1.1 (0.7-1.8) 0.8 (0.4-1.5) 
Jaundice 1.4 (1.0-1.9) 1.3 (0.9-2.0) 1.4 (0.9-2.3) 1.4 (0.8-2.3) 
Sepsis 1.1 (0.4-3.6) 0.8 (0.3-2.5) 1.9 (0.7-5.6) 1.5 (0.6-4.0) 
*Adjusted for sex, race, insurance type, year, census division, urban rural status  
 
Table 27: Logistic regression model: Examination of factors affecting emergency 
department visits in infants with NOWS 
 Any emergency 
department visit 
30-day emergency 
department visit 
 Unadjusted Adjusted Unadjusted Adjusted 
 OR (95% 
C.I.) 
OR (95% 
C.I.) 
OR (95% 
C.I.) 
OR (95% 
C.I.) 
Treated-For-NOWS 1.6 (1.02-
2.8) 
1.4 (0.9-2.1) 1.4 (0.8-2.4) 1.0 (0.5-2.0) 
LOS 1.0 (0.99-
1.0) 
1.0 (0.98-
1.01) 
1.01 (1.0-
1.03) 
1.0 (0.99-
1.03) 
Received phenobarbital 0.7 (0.4-1.4) - 0.4 (0.1-1.4) - 
Received benzodiazepine 1.6 (0.6-4.0) 0.2 (0.5-2.9) 0.9 (0.1-6.2) 0.8 (0.2-3.9) 
Any respiratory condition 1.4 (0.8-2.2) 1.1 (0.8-1.5) 1.9 (1.1-3.3) 1.6 (0.8-2.9) 
Feeding difficulties 1.2 (0.8-1.8) 1.0 (0.7-1.5) 1.2 (0.6-2.2) 0.7 (0.4-1.4) 
Prematurity 1.2 (0.8-1.8) 1.0 (0.7-1.5) 1.4 (0.8-2.4) 1.2 (0.7-2.0) 
Received antibiotic 1.3 (0.8-2.0) 1.0 (0.7-1.5) 1.4 (0.7-2.5) 0.9 (0.4-2.0) 
Jaundice 1.1 (0.7-1.6) 1.0 (0.7-1.4) 1.2 (0.7-2.1) 1.0 (0.6-1.7) 
Sepsis 1.3 (0.7-2.3) 1.1 (0.6-2.1) 1.9 (0.6-6.1) 1.5 (0.5-4.7) 
*Adjusted for sex, race, insurance type, year, census division, urban rural status  
 
100 
 
Table 28: Logistic regression model: Examination of factors affecting any composite visit 
in infants with NOWS 
 Any visit (Emergency 
department or 
rehospitalization) 
Any 30-day visit 
(Emergency department 
or rehospitalization) 
 Unadjusted Adjusted Unadjusted Adjusted 
 OR (95% 
C.I.) 
OR (95% 
C.I.) 
OR (95% 
C.I.) 
OR (95% 
C.I.) 
Treated-For-NOWS 1.4 (0.99-
2.3) 
1.2 (0.8-1.9) 1.1 (0.7-1.6) 0.9 (0.5-1.6) 
LOS 1.0 (1.0-
1.02) 
0.99 (0.98-
1.01) 
1.0 (1.0-
1.02) 
1.0 (0.99-
1.02) 
Received phenobarbital 0.6 (0.3-1.2) - 0.4 (0.1-1.1) - 
Received benzodiazepine 2.1 (1.1-3.8) 1.7 (0.8-3.4) 1.9 (0.9-4.1) 1.8 (0.7-4.8) 
Any respiratory condition 1.5 (1.1-2.0) 1.2 (0.9-1.6) 1.8 (1.2-2.9) 1.6 (0.96-
2.6) 
Feeding difficulties 1.3 (0.9-1.8) 1.1 (0.8 -1.5) 1.4 (0.8-2.3) 1.0 (0.7-1.3) 
Prematurity 1.2 (0.8-1.6) 0.9 (0.7-1.3) 1.2 (0.8-1.7) 0.9 (0.6-1.4) 
Received antibiotic 1.4 (0.9-2.0) 1.1 (0.8-1.5) 1.3 (0.9-1.9) 0.9 (0.6-1.5) 
Jaundice 1.1 (0.9-1.5) 1.1 (0.9-1.4) 1.3 (0.9-1.8) 1.1 (0.8-3.2) 
Sepsis 1.3 (0.7-2.3) 1.1 (0.6-1.9) 2.1 (0.9-4.6) 1.5 (0.7-3.2) 
*Adjusted for sex, race, insurance type, year, census division, urban rural status  
 
Table 29: Logistic regression model: Examination of factors affecting any outpatient visits 
in infants with NOWS 
*Adjusted for sex, race, insurance type, year, census division, urban rural status   
 Any outpatient visit 
 Unadjusted Adjusted 
 OR (95% C.I.) OR (95% C.I.) 
Treated-For-NOWS 1.0 (0.7-1.4) 1.0 (0.7-1.5) 
LOS 1.0 (0.97-1.0) 1.0 (0.98-1.01) 
Received phenobarbital 0.6 (0.2-1.1) - 
Received benzodiazepine 1.9 (0.7-5.0) 2.6 (1.2-5.2) 
Any respiratory condition 1.1 (0.8-1.5) 1.1 (0.8-1.5) 
Feeding difficulties 1.2 (0.8-1.9) 1.1 (0.8-1.5) 
Prematurity 1.0 (0.7-1.4) 0.9 (0.7-1.2) 
Received antibiotic 1.3 (0.9-1.8) 0.1 (0.7-1.5) 
Jaundice 0.7 (0.5-0.97) 1.1 (0.8-1.1) 
Sepsis 0.9 (0.5-1.6) 0.7 (0.4-1.3) 
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4.3.4 Analysis of the association between NOWS related severity measures and rates of 
post-discharge health care utilization: Zero-inflated Poisson regression models 
In Table 30, the association between NOWS severity measures and rates of post-
discharge health care utilization during the one-year follow-up is reported. In the 
unadjusted model, the infants who received pharmacologic treatment for NOWS (IRR: 1.5, 
95% C.I.: 1.01-1.4) and had respiratory condition (IRR: 1.5, 95% C.I.: 1.2-1.8) had higher 
incidence rates for any composite visit. In the full model, presence of a respiratory 
condition was associated with a statistically significant increase in incidence of any 
composite visit (IRR: 1.2, 95% C.I.: 1.04-1.5) compared to those who did not have a 
respiratory condition. Further, infants who received antibiotics, those who had a diagnosis 
of a respiratory condition, and feeding difficulties also had higher incidence rates of 
rehospitalization. In the full model, there was a marginal effect of respiratory condition on 
increase in incidence of any rehospitalization in the NOWS group (IRR: 1.7, 95% C.I.: 1.0-
2.7). In the unadjusted model, infants who had a respiratory condition had higher incidence 
rates of emergency department visits (IRR: 1.4, 95% C.I.: 1.04-1.8). Infants with feeding 
difficulties had higher incidence rates of outpatient visits (IRR: 1.5, 95% C.I.: 1.2-1.8). The 
association remained significant after adjustment for other factors in the full model. 
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Table 30: Zero-inflated Poisson regression model: Analysis of factors affecting rates of 
post-discharge health care utilization in infants with NOWS 
 Any visit Rehospitalizati
on 
Emergency 
department 
Outpatient 
visits 
 IRR (95% C.I.) 
Zero inflated Poisson model (unadjusted) 
Treated-For-NOWS 1.5 (1.01-1.4) 1.2 (0.7-1.9) 1.7 (1.0-2.7) 1.2 (0.97-1.5) 
LOS 1.0 (0.99-1.01) 1.0 (0.99-1.01) 1.0 (0.99-1.02) 1.0 (0.98-1.0) 
Received 
phenobarbital 
0.6 (0.3-1.1) 0.4 (0.1-1.1) 0.6 (0.3-1.1) 1.2 (0.8-1.7) 
Received 
benzodiazepine 
1.2 (0.7-2.1) 2.3 (0.9-5.6) 1.2 (0.6-2.4) 1.1 (0.5-2.3) 
Any respiratory 
condition 
1.5 (1.2-1.8) 1.9 (1.1-3.1) 1.4 (1.04-1.8) 1.0 (0.8-1.4) 
Feeding difficulties 1.1 (0.8-1.4) 1.5 (1.1-2.0) 1.0 (0.7-1.2) 1.5 (1.2-1.8) 
Prematurity 1.3 (0.99-1.7) 0.2 (0.8-1.9) 1.2 (0.99-1.5) 0.9 (0.7-1.3) 
Received antibiotic 1.2 (0.9-1.5) 1.6 (1.1-2.2) 1.1 (0.8-1.5) 0.9 (0.7-1.3) 
Jaundice 1.1 (0.9-1.3) 1.4 (1.0-1.8) 1.0 (0.8-1.3) 0.9 (0.7-1.1) 
Sepsis 0.9 (0.6-1.5) 1.0 (0.3-2.9) 0.9 (0.6-1.5) 0.5 (0.3-0.9) 
     
Zero inflated Poisson model (adjusted)* 
Treated-For-NOWS 1.2 (0.8-1.7) 0.9 (0.5-1.5) 1.4 (0.9-2.2) 1.1 (0.9-1.5) 
LOS 1.0 (0.99-1.01) 1.0 (0.99-1.01) 1.0 (0.98-1.02) 1.0 (0.99-1.0) 
Received 
benzodiazepine 
1.5 (0.8-2.8) 2.6 (0.9-7.6) 1.2 (0.5-2.7) 1.2 (0.7-2.1) 
Any respiratory 
condition 
1.2 (1.04-1.5) 1.7 (1.0-2.7) 1.1 (0.9-1.4) 1.0 (0.7-1.5) 
Feeding difficulties 0.9 (0.7-1.2) 1.3 (0.9-1.6) 0.8 (0.6-1.1) 1.5 (1.2-1.8) 
Prematurity 1.1 (0.8-1.4) 1.0 (0.6-1.5) 1.1 (0.8-1.4) 0.9 (0.7-1.3) 
Received antibiotic 1.1 (0.8-1.5) 1.3 (0.9-1.9) 1.1 (0.7-1.6) 0.8 (0.6-1.0) 
Jaundice 1.1 (0.9-1.4) 1.3 (0.9-1.8) 1.0 (0.8-1.3) 1.0 (0.8-1.2) 
Sepsis 0.9 (0.5-1.6) 0.7 (0.2-1.9) 1.0 (0.6-1.9) 0.5 (0.3-0.8) 
IRR: Incidence rate ratio 
*Adjusted for sex, race, insurance type, urban-rural status, census division, hospital size, 
year of discharge 
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4.3.4 Operationalization of LOS: the non-linear effect of LOS on post-discharge 
healthcare utilization: 
LOS was operationalized by four transformations to account for possible non-linear 
effects on post-discharge healthcare utilization. We observed a non-linear effect of LOS 
on short-term post-discharge health care utilization. As presented in Figure 9, within the 
NOWS group, the probability of any event in the 30-day post-discharge period varied for 
emergency room visits and rehospitalization. The probability of emergency room visits 
decreases when LOS increases from three to four days to five to six days. This probability 
increased with increasing LOS. The risk then stabilizes at infants with LOS more than 20 
days. For hospital readmission, the risk is significantly higher for infants with short LOS 
(risk increases exponentially for age at discharge 3 to 7 days. The risk decreases as the LOS 
increases to at least 10 to 15 days. After 15 days, the risk increases along with LOS. The 
heterogeneity of non-linear risk for emergency room visit, and rehospitalization limits the 
interpretation of non-linear association between LOS and composite post-discharge 
healthcare utilization.  
It should also be taken into account that using non-linear transformation for LOS 
could lead to overfitting. This is more likely in the event that prematurity, pharmacological 
treatment for NOWS, and other diagnoses are factored into a regression model. With this 
information available, it is possible that a linear form of LOS could sufficiently describe 
the variation in post-discharge health care utilization in the NOWS group.
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Figure 9: Assessing the non-linear relationship between infant length of stay and short-term post-discharge healthcare utilization 
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4.4 Sensitivity analysis:  
4.4.1 Examination of the effect of LOS as a selection criterion on post-discharge 
healthcare utilization 
Approximately 25% of the infants in the late preterm group had LOS less than three 
days. We classified the late preterm group into two categories (i.e., LOS less than three 
days and LOS more than or equal to three days) to compare their post-discharge health care 
utilization. Besides any emergency visits, the rates of post-discharge health care utilization 
were higher (p<0.05) in the infants with LOS less than three days across all other outcomes 
(Table 31).  
In our selection criteria, we had excluded NOWS infants with LOS less than three 
days. As the LOS was shown to affect post-discharge healthcare utilization, the inclusion 
of infants with LOS less than 3 days in the late preterm group could have led to differences 
in post-discharge health care utilization. We performed a sensitivity analysis to compare 
the differences in post-discharge health care utilization between NOWS group and the late 
preterm group after the exclusion of infants in the late preterm group whose LOS was less 
than three days. The results are shown in Table 32. 
Based on the sensitivity analysis, we observed that the exclusion of late preterm 
infants with LOS less than 3 days did not produce a significant difference in the post-
discharge health care utilization across the two study groups. In some of the comparisons 
(e.g.: 30-day rehospitalization, any rehospitalization) there were substantial changes in the 
p-value across the sensitivity analysis. These changes were likely due larger change in the 
proportion of rehospitalization events in the sensitivity analysis. 
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We performed a multivariable logistic regression to assess if any confounders were 
affecting the results we observed from the sensitivity analysis (Table 34). In the original 
analysis (Comparison of post-discharge health care utilization in NOWS group vs. late 
preterm group: Tables 15, 16, and 17) there were statistically significant differences in 
post-discharge health care utilization between NOWS and late preterm group after 
adjustment for confounders. Specifically, NOWS group had lower odds of any 
rehospitalization and any composite visit. After excluding late preterm infants with LOS 
less than 3 days, the association was still observed to be statistically significant but the 
point estimate of the odds ratio was slightly lower (Table 33). Based on these findings we 
can conclude that there is heterogeneity with respect to post-discharge health care 
utilization in the late preterm group based on the LOS of the infant. However, the 
differences did not substantially affect the comparison of post-discharge healthcare 
utilization between NOWS and late preterm groups. 
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Table 31: Proportion of late preterm infants who had post-discharge healthcare utilization 
stratified by LOS (cut-off <3 days) 
 Any 
emergency 
Any 
rehospitalization 
Any 
visit 
30-day 
emergency 
30-day 
rehospitalization 
Any 
30-day 
visit 
       
LOS < 3 
days 
8.1% 4.8% 12.1% 2.3% 3.9% 6.0% 
LOS ≥ 3 
days 
7.7% 3.9% 10.8% 1.7% 2.4% 3.9% 
P-value 0.31 0.003 0.008 0.002 <0.001 <0.001 
 
Table 32: Sensitivity analysis: Differences in post-discharge healthcare utilization in 
NOWS group compared to late preterm group 
 Any 
emergency 
Any 
rehospitalization 
Any 
visit 
30-day 
emergency 
30-day 
rehospitalization 
Any 
30-day 
visit 
   
NOWS 7.5% 3.8% 10.4% 2.0% 2.4% 4.3% 
Late 
preterm  
7.6% 4.3% 11.1% 1.8% 2.9% 4.5% 
P-value 0.86 0.21 0.19 0.23 0.07 0.48 
Sensitivity analysis (late preterm LOS ≥ 3 days) 
NOWS 7.5% 3.8% 10.4% 2.0% 2.4% 4.3% 
Late 
preterm  
7.7% 3.9% 10.9% 1.7% 2.4% 3.9% 
P-value 0.69 0.74 0.36 0.13 0.94 0.36 
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Table 33: Sensitivity analysis: Logistic regression: Post-discharge healthcare utilization 
in NOWS group compared to late preterm group 
 
Any emergency Any 
rehospitalization 
Any visit 
 
OR (95% C.I.) 
Late preterm (Ref) vs. 
NOWS  
0.8 (0.7 - 1.1) 0.8 (0.6 - 0.) 0.8 (0.6 – 
0.97) 
Sensitivity analysis (late preterm LOS ≥ 3 days) 
Late preterm (Ref) vs. 
NOWS  
0.9 (0.7 - 1.1) 0.8 (0.7 - 1.0) 0.8 (0.7 - 
0.99) 
 
 Emergency visit 
(30-day) 
Rehospitalization 
(30-day) 
Any visit (30-
day) 
 OR (95% C.I.) 
Late preterm (Ref) vs. 
NOWS  
1.1 (0.9 - 1.5) 0.7 (0.5 - 1.0) 0.9 (0.7 - 1.1) 
Sensitivity analysis (late preterm LOS ≥ 3 days) 
Late preterm (Ref) vs. 
NOWS  
1.1 (0.9 - 1.6) 0.9 (0.7 - 1.2) 1.0 (0.8 - 1.3) 
Logistic regression model adjusted for sex, insurance type, race, urban rural status, census 
division and year. 
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4.4.2 Assessment of the difference in rates of pharmacological treatment of NOWS across 
different hospitals and its impact on post-discharge health care utilization 
In 55.8% of the hospitals, the rates of pharmacological management of NOWS was 
less than 25%, which is surprisingly low. We categorized the study sample into two groups: 
a) infants admitted/born at a hospital where ≥25% of NOWS cases received 
pharmacological treatment (n=2,029) b) infants admitted/born at a hospital where <25% of 
NOWS cases received pharmacological treatment (n=1,497). There were no statistical 
differences in the geographical distribution, urban rural status, and size (number of beds) 
of these hospital groups.  
We conducted a sensitivity analysis to examine the differences in the post-discharge 
healthcare utilization across between these two hospital groups. The outcome variables that 
were examined were 30-day composite (emergency department visit or hospital 
readmission) healthcare utilization and any composite healthcare utilization. We observed 
significantly higher composite health care utilization (one-year follow-up period) in infants 
who were admitted/born into a hospital where more than 25% of the NOWS diagnosed 
infants received pharmacological treatment compared to the group where pharmacological 
NOWS treatment rate was less than 25% (Any composite visit during one-year follow-up 
period: 12.7% vs. 7.2%, p<0.001). There was no difference in 30-day composite health 
care utilization across these two hospital groups (Table 34). 
We restricted our sample to infants who were admitted to hospitals where the 
pharmacological treatment rate was ≥25% and compared their post-discharge health care 
utilization with the uncomplicated birth and late preterm groups. After the application of 
the exclusion criteria, the remaining NOWS group (infants managed in hospitals where 
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NOWS treatment rates were more than or equal to 25%) had higher odds of one-year 
composite health care utilization compared to uncomplicated birth group in the unadjusted 
analysis (OR: 1.9, 95% C.I.: 1.4-2.5). However, the association was not statistically 
significant after adjusting for other covariates (Model 2 and Model 3 as explained in the 
methods section). The NOWS group had higher odds of 30-day composite health care 
utilization compared to compared to uncomplicated birth group across all the unadjusted 
and adjusted logistic regression models (Model 3: OR: 1.4, 95% C.I.: 1.02-1.8). 
Furthermore, we also evaluated the association between pharmacological treatment 
and post-discharge health care utilization stratified across these hospital groups (Table 35). 
There was no difference in the composite healthcare utilization (both 30-day and one-year) 
based on the pharmacological treatment when stratified by the hospital groups in the 
unadjusted analysis. However, after controlling for other factors we observed that in 
hospitals that had lower treatment rates of NOWS, pharmacological treatment of NOWS 
was associated with lower odds of 30-day composite health care utilization (OR: 0.3, 95% 
C.I.: 0.1-0.8).  
The results from the sensitivity analysis were similar to the findings obtained in the 
main analysis (Table 17). We do note that there were some differences in the health care 
utilization in infants based on the hospital they were treated. The regression models in our 
study utilizes a hospital random effects model (cluster effects of hospital) which would 
take into account these differences in outcomes. 
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Table 34: Sensitivity analysis: Proportion of infants in the NOWS group who had any 
composite healthcare utilization based on NOWS pharmacological treatment rates (<25%) 
of hospitals 
 Facilities with ≥25% 
of NOWS cases 
treated 
Facilities with <25 of 
NOWS cases treated  
p-value 
Any visit 12.7% 7.2% <0.001 
Any 30-day visit 4.7% 3.7% 0.143 
  
Table 35: Sensitivity analysis: Logistic regression model: Association between post-
discharge health care utilization and pharmacological treatment of NOWS stratified by 
NOWS treatment rates (<25%) of hospitals 
  Facilities with ≥25% of NOWS 
cases treated 
Facilities with <25 of NOWS 
cases treated 
Variable: Treated-
For-NOWS 
Any visit 
OR (95% C.I.) 
Unadjusted model 1.3 (0.86 - 1.9) 0.7 (0.2 - 2.6) 
Adjusted model 1.3 (0.83 - 2.1) 0.5 (0.2 - 1.6) 
   
 
Any 30-day visit 
OR (95% C.I.) 
Unadjusted model 1.1 (0.6 - 1.9) 0.5 (0.3 - 1.1) 
Adjusted model 1.1 (0.6 - 2.1) 0.3 (0.1 - 0.8) 
*Adjusted for sex, race, insurance type, year, census division, urban rural status  
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4.4.3 Propensity score analysis for pharmacological management of NOWS: 
 Propensity scores for pharmacological treatment for NOWS were generated by 
using the process described in the method section. The propensity score was used as a linear 
covariate along with the pharmacological treatment for NOWS variable as predictor for 
post-discharge health care utilization (any composite visit, any 30-day composite visit). 
After adjusting for the propensity score, pharmacological treatment of NOWS was 
associated with higher odds of any composite visit (OR: 1.4, 95% C.I.: 1.04-1.7) compared 
to no pharmacological treatment. There was no association between pharmacological 
treatment for NOWS and any 30-day composite health care utilization after adjusting for 
propensity scores (OR: 0.9, 95% C.I.: 0.6-3).  
4.4.4 Principal component analysis for NOWS severity factors: 
The principal component analysis with pharmacological treatment of NOWS, LOS, 
medications used (benzodiazepines), respiratory conditions, and feeding difficulties as 
input variables yielded principal components which are listed in Table 36. The Table shows 
the first three components where the eigenvalues are >1 and the absolute values of factor 
loadings are >0.3. The first factor is loaded by pharmacological treatment of NOWS, LOS, 
and feeding problems. The second factor is loaded with pharmacological treatment of 
NOWS, use of benzodiazepines, respiratory condition of newborn, and feeding problems. 
The third factor is loaded by transient tachypnea of newborn, respiratory distress syndrome, 
respiratory condition of newborn, and other specified respiratory conditions. These three 
components described a total of 49.5% of the variation of in the input variables.  
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Table 36: Results of principal component analysis: components and factor loadings 
Variable Component 1 Component 2 Component 3 
Treated-For-NOWS 0.50 -0.36  
LOS 0.56   
Benzodiazepine use  -0.45  
Respiratory distress 
syndrome 
  -0.51 
Transient Tachypnea of 
newborn 
  0.52 
Respiratory condition of 
newborn (unspecified) 
 0.49 -0.35 
Other specified 
respiratory condition 
  -0.58 
Feeding problems 0.42 0.31  
 
 These components were considered NOWS severity measures (uncorrelated) and 
their association with post-discharge health care utilization was examined (Table 37). We 
observed that the first component was significantly associated with higher odds of any 
composite visit during the one-year follow-up period (OR: 1.2, 95% C.I.: 1.1-1.3). The 
same component was significantly associated with any 30-day composite visit (OR: 1.2, 
95% C.I.: 1.1-1.3).  
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Table 37: Logistic regression model: Association between post-discharge health care 
utilization and principal components as measure of NOWS severity 
 Any visit Any visit* Any 30-day 
visit 
Any 30-day 
visit* 
 OR (95% C.I.) 
Component 1 1.2 (1.1-1.2) 1.1 (1.04-1.2) 1.2 (1.1-1.3) 1.1 (0.99-1.3) 
Component 2 1.0 (0.9-1.1) 1.0 (0.9-1.1) 1.1 (0.98-1.3) 1.1 (0.95-1.2) 
Component 3 1.0 (0.9-1.1) 0.9 (0.9-1.03) 1.0 (0.9-1.1) 1.0 (0.8-1.2) 
*Adjusted for prematurity, sepsis, jaundice, use of antibiotics, sex, insurance status, race, 
bed size, year, and census division
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CHAPTER 5: DISCUSSION 
In this chapter, we discuss the findings of our study. Discussion of the results is 
presented first and divided based on the specific aims of the study, followed by the 
limitations of the study, the study’s impact and future directions.  
5.1: Discussion for Specific Aim 1 
The trends and geographic distribution of NOWS births matched the growing 
opioid epidemic in the US. Between 2011 and 2016, the incidence of NOWS increased 
approximately four fold in several census divisions in the US. Results from our analysis 
show that rates of NOWS are consistently above 15 per 1000 births and reach up to, and 
over, 30 per 1000 births in New England, Middle Atlantic, East South Central, and South 
Atlantic regions. In contrast, during the same period, the rates of late preterm birth 
remained relatively constant at approximately 6 per 100 births.  
The growing rate of NOWS reflects the ongoing opioid epidemic in the US. 
Increasing rates of opioid prescription across the U.S. has been shown by previous 
reports.108-111. Data has recently shown a peak in illicit opioid use (heroin and other 
synthetic opioids) in the northeast U.S. around the year 2015, dramatically increasing the 
opioid overdose rates in large swaths of communities across that region.112 The increase in 
illicit opioid use and misuse of prescription opioids in the general population was matched 
by an increase in opioid use during pregnancy, which closely correlates to increase in the 
rates of NOWS. Using the Healthcare Cost and Utilization project (HCUP) Kids data, 
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Patrick et al. reported a three-fold increase in the rates of NOWS between the years 2009 
and 2012 across the US.43,113  
Figure 10 shows the rates of NOWS derived from our findings compared to the 
previous studies. Patrick et al. reported an increase in the rates of NOWS from 
approximately 1.2 per 1000 births in the year 2000 to approximately 3.5 per 1000 births in 
the year 2009.25 A similar growth of substance use disorder in mothers at delivery was 
reported by Haight et al.114 Additionally, the rates of NOWS reported by Winkelman et al113 
show significant overlap with the estimates reported by Patrick et al. (years 2004-2009). 
The rates of NOWS observed in our study were significantly higher compared to the rates 
reported by Winkelman et al. during the same study period. The denominator used for the 
estimate of NOWS rates in our study is a subset of the total number of births that actually 
occurred, which can cause the rates of NOWS to be potentially overestimated. Additionally, 
the hospitals/health centers that were included in the study are not specifically weighted to 
represent total national births, which may also cause the rates obtained in our study to be 
different than previous estimates. 
117 
 
Figure 10: Comparison of estimates of NOWS birth with results from existing literature 
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There is a wide variability in the prescribing patterns of opioids across different 
states in the US, which has led to significant variability in the incidence of NOWS across 
the country. The geographic variability in NOWS incidence in our study are in accord with 
findings from previous studies and matches the variation in the incidence of opioid 
epidemic in the US.43,115 These reports show that the rates of opioid use are closely related 
to the rates of NOWS, and policies that address the opioid epidemic could lead to lower 
rates of NOWS. 
Infants with NOWS differed significantly in terms of their baseline characteristics 
compared to uncomplicated births and late preterm births. A higher proportion of infants 
diagnosed with NOWS were Caucasian (79%) compared to late preterm birth and 
uncomplicated births (53% and 57%, respectively). This difference in the rates of NOWS 
reflects the difference in rates of opioid use, which has been reported to be higher in non-
Hispanic Whites.111 Our study also showed that Medicaid covered a majority of NOWS 
cases (approximately 69%). Previous studies have reported similar findings, with one study 
reporting up to 80% of the NOWS related payments were covered by Medicaid.44 
Furthermore, our study shows that a majority of the NOWS births occurred in medical 
centers/hospitals with a bed size of 300 or more. Infants with NOWS usually require a 
greater level of medical attention, pharmacological management, and higher rates of 
admission to the NICU to manage symptoms related to NOWS. This would require 
admission to large hospital systems where these services are available, thus reflecting the 
difference in the birthing hospital. 
As expected, there were significant differences in healthcare utilization in infants 
who were diagnosed with NOWS at birth compared to both control groups. If in utero 
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exposure to opioids is confirmed, the patients are required to stay in the hospital for an 
extended observation period (ranging from 72 to 96 hours) to examine the symptoms of 
NOWS. Infants who are diagnosed with NOWS require significant pharmacologic and 
non-pharmacologic management of the symptoms, which prolongs their hospital stay. For 
infants requiring pharmacologic treatment, the LOS depends upon the severity of NOWS, 
the amount of opioid treatment required to manage the symptoms, and any additional 
complications present at birth. Similar to findings from previous studies, our study showed 
that the average LOS for infants diagnosed with NOWS is approximately 15 days.  
The amount of additional care required for NOWS is also reflected in the average 
cost of the management of NOWS. There was a significant difference in cost (total charges) 
for NOWS births compared to uncomplicated births (approximate median charges: 
$24,900 vs. $3,100). The cost of management of late preterm birth was similar to NOWS, 
as similar degrees of medical attention were needed for both groups. Furthermore, 
respiratory problems, sepsis, and feeding difficulties were common in the late preterm 
group. These conditions require greater medical attention and specialized care, which leads 
to longer hospital stays and higher cost of treatment.  
Post-discharge health care utilization in infants with NOWS showed consistent 
trends over different measures of healthcare utilization. There was an increase in the rates 
of post-discharge health care utilization in the NOWS group between the years 2011 and 
2013 (from 8.5% to 13% for any composite visit and from 2.1% to 6.7% for any 30-day 
composite visit), whereas the post-discharge rates in the late preterm group and 
uncomplicated birth group remained fairly constant. This could have probably been 
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because of the surge in the incidence of NOWS in that period while there were not enough 
measures available in the hospitals to effectively diagnose and manage infants with NOWS.   
Our study found that approximately 4% of infants with NOWS had hospital 
readmission, compared to about 1.5% of the two control groups. Patrick et al. reported that 
the overall one-year readmission rates in infants with NOWS was approximately 7.5% 
compared to 4% in controls.36 While absolute readmission rates for the NOWS group in 
our study were lower than that reported by Patrick et al., the ratio of readmission between 
the NOWS and uncomplicated birth groups was approximately the same. Infants with 
NOWS had significantly higher odds of hospital readmission compared to controls for both 
one-year (OR: 1.7, 95% C.I. 1.3-2.2) and 30-day rehospitalizations (OR: 1.9 95% C.I.: 1.3-
2.6). Similar findings were reported by Patrick et al. 2015 (30-day rehospitalization: OR: 
2.5, 95% C.I.: 1.8-3.6)36, Hwang et al. (OR: 1.1: 95% C.I.: 1.04-1.2)116 and Liu et al. 
(adjusted mean ratio: 4.2, 95% C.I.: 1.9-9.7)117. Using the Zero-inflated Poisson regression 
models, consistent results were observed in the incidence rates of rehospitalizations for the 
NOWS groups compared to the uncomplicated birth group. This evidence suggests 
increased rehospitalization during the period surrounding the first year of life for the 
NOWS group.   
We observed higher rates of emergency department visits in the NOWS group 
compared to the uncomplicated birth group, though, not as pronounced as the difference in 
rehospitalizations between the groups. In the adjusted model, a marginally significant 
association was observed for 30-day emergency department visits. Liu et al. reported an 
adjusted mean ratio of 1.8 (95% C.I.: 1.5-2.2) for emergency department visit claims in the 
ages between 4 and 12 months.117 Hwang et al. reported lower odds of emergency 
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department visits in infants born to mothers with substance use disorders compared to 
controls.116 However that study was not specific to withdrawal syndrome related to opioids, 
which could have contributed to differences in the estimates of emergency department 
visits.   
The differences in the estimates of post-discharge health care utilization may have 
been observed due to a multitude of reasons. First, the selection criteria of NOWS group 
in our study was significantly different compared to Patrick et al. study. Our study applied 
additional exclusion criteria to the NOWS group, such as LOS less than three days or more 
than 60 days. Patrick et al. had reported that NOWS infants with LOS less than seven days 
had comparatively higher rates of rehospitalization than those who had longer hospital 
stays (up to 28 days). Our study excluded those who did not have hospital stays of more 
than or equal to three days, which may have led to the differences between the two studies. 
Second, the differences in effect size may also stem from where the infants may seek care 
for health related problems. Since the information for any utilization is only captured when 
the infant visits a center that specifically uses the CERNER EHR system, information about 
all post-discharge visits may not be available. Assuming that the choice of accessing a 
health center for emergency visit is random across the study groups (i.e. the probability of 
choosing a health center that utilizes CERNER EHR is the same for NOWS group and 
uncomplicated birth group), the effect size will be biased towards the null. Therefore, we 
can speculate that the association between NOWS and emergency department visits has 
been underestimated. 
In comparison to mostly “unplanned” visits, such as emergency department visits 
or rehospitalizations, the proportion of infants who had outpatient visits was similar in the 
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NOWS group compared to the uncomplicated birth group. In the adjusted model, there was 
no significant association between outpatient visit and diagnosis of NOWS. Additionally, 
the absolute prevalence of any outpatient visit in NOWS group was lower than the 
uncomplicated birth group. Liu et al. reported adjusted mean ratio of 1.1 (95% C.I.: 1.1-
1.2) claims for outpatient claims in infants diagnosed with NOWS.117 It should be noted 
that the Liu et al. study was based on the analysis of commercial claims data. Since 
approximately 80% of the initial NOWS related birth costs are covered by Medicaid, 
population-based study of infants who had commercial insurance could contribute to these 
differences in findings. Furthermore, there is evidence of lower rates of child health 
services use in infants born to mothers with substance use disorder.86 It is likely that in the 
NOWS group, the higher number of emergency department visits and rehospitalization, 
could be due to lack of or insufficiently planned routine health-care visits (e.g.: outpatient 
visits and well-baby visits). Other possible reasons could be constraints on access to care 
such as distance, availability of appointments.  
A multitude of factors can affect emergency department or rehospitalization visits 
after discharge in the first year of the infant’s life.41,118-122 These factors range from initial 
length of hospital stay following birth, the type of insurance used, the infant’s sex, and 
socioeconomic factors. In addition, the presence of certain medical conditions at birth, such 
as preterm birth, feeding difficulties, jaundice, convulsions, sepsis and respiratory 
problems, are also known to increase the risk of emergency department visits and 
readmissions to a health care facility. These factors were adjusted in the multivariable 
models in our study. Factors relating to the infants family such as maternal health, socio-
economic status, nutrition, and social support mechanism are also factors that could 
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potentially affect the health of an infant. The lack of these information in our study warrants 
additional research. 
In sub-group analysis, there were minor differences between the NOWS group and 
the late preterm group regarding health care utilization. The NOWS group had marginally 
lower hospital readmissions (adjusted OR: 0.8, 95% C.I.: 0.6-0.98) and any composite 
visits (adjusted OR: 0.8, 95% C.I.: 0.6-0.98). Furthermore, we examined the effect of 
difference in inclusion criteria across NOWS and late preterm group. After excluding 
infants with LOS less than 3 days from the late preterm, group we observed some changes 
in the differences in the estimates of effect size. However, the direction of association 
remained the same. 
The evidence suggests that during the one-year follow-up period, the NOWS and 
late preterm group had similar profiles regarding health care utilization. While the etiology 
and management protocols for these two groups varies, these groups face similar medical 
problems during their initial stay in the hospital. Thus, inclusion of late preterm birth as a 
control group in this study is justified. The evidence suggests that regardless of the 
etiology, early life medical conditions potentially lead to higher levels of health care 
utilization in the formative years of an infant’s life.  
5.2: Discussion for Specific Aim 2 
There is limited evidence regarding the impact of NOWS severity on long-term 
health care utilization. The severity of NOWS was determined by several factors, including 
the need for pharmacological management of NOWS, length of hospital stay following 
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birth, need for the administration of second line agents (e.g.: phenobarbital), and additional 
medical conditions.  
Approximately 35% of the infants received pharmacological treatment for NOWS. 
In our study, this was defined as receiving any methadone, morphine, tincture of opium, or 
phenobarbital. Previous studies have reported a wide variation regarding the need for 
pharmacological treatment for infant’s with NOWS. Research indicates this number ranges 
from 15% to 90%.37,115,123 Varying definitions of what constitutes “pharmacological 
management of NOWS,” (e.g.: if phenobarbital or clonidine were considered 
pharmacological treatment) could be a possible reason for this variation. While minor 
differences in demographic variables were observed in the Treated-For-NOWS and Not-
Treated-For-NOWS groups, there were significant differences in the NOWS severity 
measures between the two groups. Those infants who received pharmacologic treatment 
for NOWS had longer LOS and higher costs related to their initial hospital stay than those 
who did not. Additionally, a higher proportion of those who received pharmacologic 
treatment had respiratory problems, convulsions, feeding difficulties, and sepsis, thereby 
requiring more treatment during their initial stay.  
A significantly higher proportion of infants in the Treated-For-NOWS group had 
emergency department visits within 30-days of discharge (10% vs. 6.2%, p<0.001) as well 
as any composite visits (13% vs. 9%, p <0.001), compared to those in the Not-Treated-For-
NOWS group. Higher number of emergency department visits could have potentially 
driven this difference. These differences were not sustained in the adjusted model, which 
suggests that these associations were confounded by other factors. 
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LOS, administration of other adjunctive therapies, and the presence of medical 
conditions (respiratory problems, feeding difficulties) were considered as severity 
measures of NOWS. These severity measures could potentially affect post-discharge 
healthcare utilization in infants with NOWS. This assessment was based on the hypothesis 
that severity of NOWS could translate to higher health care utilization later in life. Previous 
research has shown that the LOS at time of birth, has a non-linear effect on post-discharge 
hospitalization in infants with NOWS.36 Similarly, other studies examining this impact for 
those born prematurely, reported the potential of unmeasured confounding in the use of 
LOS as a predictor for rehospitalization and had utilized time of birth as an instrumental 
variable to predict a 7-day readmission.124 In our study, we explored various designs to 
explore the effects of LOS on hospital post-discharge healthcare utilization. Linear model 
as described in the results section did not show a significant effect on post-discharge health 
care utilization based on LOS at birth. Next, we explored the quadratic form, equally 
spaced quantiles, and the cubic splines to examine LOS in the hospital at birth as a predictor 
for post-discharge health care utilization. These forms generally showed a non-linear 
effect, with increasing probability of rehospitalization observed until the LOS was 20 days. 
This could have been due to the fact that very short LOS could lead to poor management 
of NOWS. Average LOS of around 15-20 days could mean that proper care was provided 
to the infants thereby lowering the chances of post-discharge health care utilization. 
Considerable variability in the risk of post-discharge health care utilization was observed 
across the models when LOS exceeded 20 days. Longer lengths of stay (greater than 20 
days) could mean that there were other medical conditions or that the NOWS symptoms 
were very severe. This could potentially lead to higher post-discharge health care 
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utilization after the discharge. These findings are fairly consistent with the estimates 
reported by Patrick et al.36 Additional information regarding the medications and medical 
conditions diagnosed during the initial stay following birth were available in our study. 
These factors could be adjusted in full models, however, we chose to use the linear form 
of the variables in our statistical models.  
We also examined additional diagnostic codes received by those in the NOWS 
group and found that there was a consistent effect on post-discharge healthcare utilization 
regarding the presence or absence of respiratory problems in the NOWS group. It is likely 
that infants in the NOWS group with respiratory problems, require further management 
and health care services after their discharge for this medical condition. Feeding 
difficulties, jaundice, and sepsis showed a minor impact on post-discharge healthcare 
utilization. The medical conditions we used as factors potentially leading to readmission in 
the hospital have been shown by studies to be common causes for readmission in the 
hospital following birth for the general population. It is likely that the presence of 
diagnostic codes for these conditions, resulted in the proper management of these 
conditions, and minimized their long-term effects. In our study, we only included infants 
with NOWS who remained in the hospital for at least three days following birth. That 
criterion allowed sufficient time of observation in order to diagnose, or rule out, medical 
conditions that could lead to higher rates of early rehospitalization or emergency 
department visits.  
Overall, analysis of factors relating to NOWS severity showed limited association 
with post-discharge healthcare utilization during a follow-up period of one-year. This 
finding may have been observed due to multiple reasons. First, the presence of the 
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diagnostic codes for medical conditions, or pharmaceutical treatment, could imply that the 
condition was managed efficiently during the initial hospital stay. Thus, the likelihood of 
early health care utilization, either through an emergency department visit within 30 days 
or rehospitalization within 30 days, would be limited to extraneous conditions that would 
not be specific to NOWS. Furthermore, while the NOWS group had higher health care 
utilization overall, it is possible this is due to other conditions not directly related with 
NOWS. Examination of reasons for follow up health care encounters in infants with 
NOWS after the age of 15 days (average LOS for infants with NOWS) were revealed that 
conditions, such as acute upper respiratory tract infection, bronchitis, and cough, were 
common in the post-discharge visits. However, there was an association between the 
composite measure of NOWS severity (first principal component) and post-discharge 
health care utilization. As principal component analysis reduces the different measures of 
NOWS severity into uncorrelated composite measures, these composite measures can 
serve as better predictors in the regression models.  
It is to be noted that across all the analysis, there were significant effect of infant 
sex and insurance status on post-discharge healthcare utilization. Male infants had 
significantly higher rates of hospitalization but not emergency department visits. In 
addition, infants whose initial visits were covered through Medicaid had higher health care 
utilization. The increased utilization could be due to comparatively lower out-of-pocket 
costs. It could also be considered a marker for poor socioeconomic condition, which could 
lead to poor health of the infant, thereby increasing the risk of post-discharge health care 
utilization.  
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5.3: Limitations of the study 
Our study has several limitations. The primary limitation is the reliance on hospital 
administrative databases for the diagnosis of a medical conditions.125-127 Diagnostic codes 
are used for administrative/reimbursement purposes, and are not primarily intended for 
research purposes. However, the wealth of data collected during patients’ encounters with 
a health care system, combined with the sheer volume of the data generated in the process, 
make these administrative databases a “gold-mine” for researchers. The findings, however, 
should be interpreted with an awareness of the limitations of these databases. 
As with any retrospective data analysis, the findings of this study rely on the 
accuracy of the databases. Infants who show symptoms of withdrawal syndrome are 
assigned the ICD-9-CM code 779.5 (ICD-10-CM: P96.1). ICD-9-CM code 779.5 refers to 
“Drug withdrawal syndrome in newborn” and ICD-10-CM code refers to “Neonatal 
withdrawal symptoms from maternal use of drugs of addiction”. These codes are not 
specific to just opioid exposure. Thus, there is a likelihood of potential misclassification 
regardless of the exposure; it is possible that infants who were not exposed to prenatal 
opioids, were included in the study as those who were exposed, and led to an erroneous 
estimate of the effect size. It is important to note that withdrawal syndrome is primarily 
attributed to opioids due to the high prevalence of opioid use in the United States. Previous 
studies have noted that the use of the diagnostic codes for identification of infants with 
NOWS, has a high positive predictive value (91% for ICD-9-CM code and 98.2% for ICD-
10-CM)93. Furthermore, the use of LOS in the hospital following birth as an additional 
criterion leads to increased accuracy in diagnosing NOWS.  
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Second, this study is based on the analysis of clinical data, therefore detailed 
information on maternal health, socioeconomic status, marital status, maternal education, 
breastfeeding, and substance abuse is lacking. Type and intensity of maternal opioid 
exposure could be significant in predicting long-term health care utilization in infants with 
NOWS. There is no direct link between mother and infant records within the HF database, 
thus making this type of analysis difficult. Poor maternal health, social, and economic 
problems can lead to adverse health outcomes in infants, which could lead to increased 
health-care utilization in terms of emergency visits and rehospitalizations. Additionally, 
the same factors could impact the general care of the infant. For example, a missed general 
health-care appointment because of poor care or resources could cause greater health care 
utilization in term of emergency department visits and rehospitalization in the long run. A 
majority of infants born with a diagnosis of NOWS, have mothers who are either active 
substance users or managed on a maintenance therapy. In general, risk factors such as poor 
social support network, stigma for the society, lack of economic means, unstable housing, 
abuse, poor nutrition, behavioral health disorders, anxiety, depression, alcohol use, and 
infectious diseases (HIV/HCV) are prevalent in these populations.8,128-131 These factors, in 
combination with limited resources for the care of the infant, may lead to poor health, and 
increase the chances of health care utilization which could have been potentially avoided.  
Third, there are limitations to the estimates of the amount of treatment received by 
the infant during their hospital stay for NOWS. Initially, we sought to quantify the amount 
of opioids the infant received for management of withdrawal symptoms during their initial 
hospital stay. There were limitations in the database regarding quantification of 
medications, such as oral morphine for the management of NOWS, as the solution has to 
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be diluted several times (up to 0.04 mg/ml from original concentration of 10mg/5ml or 
5mg/5ml) before administration. While the information on the strength and timing of 
administration of morphine and methadone was available, there was no reliable 
information on dilution or the strength of the medication administered to the infants. 
Furthermore, there is no consensus on conversion of methadone to morphine equivalents, 
specifically in relation to management of NOWS. Conversion factors range from 1:3 to 1:4 
for lower doses, but the variability in conversion increases as the dose increases.132 
Fourth, a simple Poisson model does not account for the dependency of outcomes. 
For example, infants who had an emergency department visit are more likely to have 
subsequent department visits because of their medical condition. The assumption of 
independence in Poisson models is violated by these recurrent events. Additionally, when 
examining all three groups (NOWS, late preterm births, and uncomplicated births), a 
majority of the infants in the study had no emergency visits or rehospitalizations within 30-
days of discharge. This leads to a high number of zero values in the outcome variable. We 
addressed this problem by the utilization of Zero-inflated Poisson as a robust alternative to 
Poisson regression. 
Fifth, errors relating to censoring of data because they accessed care in different 
health care centers whereby their information was not captured in the Cerner HealthFacts 
database could bias the results in our study. It is likely that a fraction of a sample across all 
the study groups who required service from a healthcare center whether it may be 
emergency department visits or hospital readmission may seek care in institutions that do 
not use the CERNER EHR system. While there is a probability that this absence could lead 
to underestimation of the actual number of visits, the effect on the odds ratio of these events 
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in NOWS group compared to controls would be minimal. This is based on the assumption 
that infants would seek care from healthcare institutions irrespective of the EHR being 
utilized at that institution.  
Based on the results of our study and previous studies, let us assume that the rate 
of rehospitalization across during the follow up period in the NOWS group and the 
uncomplicated birth group is 4% and 2%, respectively. Based on this hypothetical data, the 
OR would be 2.04. Assuming that only 75% of these visits are captured in CERNER 
system, the observed OR would be 2.03. Even at a rate of 25% of these events occurring 
in a health care system that uses CERNER EHR, the observed OR would approximate 2.01. 
While the estimates of post-discharge health care observed in our study were lower than 
observed elsewhere, they were proportionately similar across the study groups. Given that 
the probability of seeking care at any given hospital is random across study groups, the 
observed effect size is very robust.  
Finally, generalizability of the study might be limited. However, our dataset spans 
hospitals and health care centers across the United States, and covers a wide range of 
demographics. Previous studies were either limited geographically, 35,36,116 or, did not 
include a majority of the infants who present with NOWS117. HF database covers over 500 
health centers across the United States, thus, increasing our study’s generalizability 
compared to previous studies.  
Even in the light of the above limitations, we believe that our study contributes to 
the existing literature relating to long-term health care utilization in infants with NOWS. 
By using a measure of the severity of NOWS as a predictor of future health care utilization, 
we have added another dimension to the study of effects of opioid withdrawal. We believe 
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that the findings of this study can lead to the formulation of policy that will ensure proper 
follow-up and evaluation of these infants. In this era of the opioid use epidemic in the 
United States, we believe that this study can contribute to the overall understanding of the 
long-term effects of prenatal opioid exposure. 
5.4: Implications of the study 
As the opioid crisis expands long-term effects of NOWS warrant greater attention. 
There are conflicting reports of the long-term impact of NOWS. Recent studies on infants 
born to women who were on MAT showed no difference in development in their early 
childhood compared to infants who were not exposed to prenatal opioids.84,85 Existing 
literature also suggests a variety of risks for infants with NOWS such as cognitive, 
behavioral deficits at young age, and poor school performance when these infants reach 
older age.83 There is limited data on post-discharge health care service utilization in infants 
who were diagnosed with NOWS.36,117 Our study shows consistent evidence of increased 
rehospitalization in infants with NOWS compared to uncomplicated birth infants in the 
one-year follow-up period after discharge. However, impact of NOWS on emergency 
department visits, and outpatient visits, is still inconsistent across studies.  
The results from our study showed that the rates of post-discharge health care 
utilization were not specific to the severity of NOWS. While certain diagnoses at birth were 
related to increased post-discharge health care utilization the association was not 
consistent. The principal component analysis in our study where the severity of NOWS 
was transformed into uncorrelated components showed consistent association with post-
discharge health care utilization. Hence, a scaled measure of NOWS severity could be vital 
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in predicting post-discharge health care utilization. Maternal substance use, poor nutrition, 
lack of social support, and poor pre/postnatal care may also lead to higher health care needs 
for these infants. Numerous studies have shown the impact of environment and family on 
the health of an infant.133 Women with substance use disorders have high rates of mental 
health disorders and unemployment, and are more likely to have a history of abuse, poor 
nutrition, and limited social support.8,86,128,129 These forces, in combination with the effects 
of opioid exposure and subsequent withdrawal effects, may contribute to higher health care 
needs and thus, health care utilization for these infants. 
Hospital readmission and emergency department visits are costly to tax-payers, 
disruptive to patients and their families, and may increase stress and financial hardships for 
patients and families as well. Closer follow-up and management of infants with NOWS is 
needed to minimize emergency department visits and unplanned rehospitalization. 
Providing additional resources and a comprehensive care environment could lead to 
improved health outcomes in infants with NOWS. It is recommended that these infants 
have regular well-child visits for evaluation of any signs of medical condition that could 
warrant proper medical care.  
5.5: Future research 
 Our study shows that infants with NOWS have a higher risk of post-discharge 
health care utilization compared to controls. Based on this piece of evidence, a two-pronged 
approach to future research is suggested. First, research should be focused towards 
reducing “preventable and unplanned” health-care utilization events and improving regular 
check-up/follow-up visits in infants who are either diagnosed with NOWS or experienced 
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in-utero exposure to opioids. Research aimed at improving the mental and physical needs 
of the mother is also recommended, as improvement in her health may translate to 
improvement in the infant’s health. Providing improved social support, ensuring ease of 
access to health services, such as treatment for OUD, counseling, proper nutrition, and 
arrangement for proper housing, may lead to increased stability in the surrounding 
environment of the infant. Studies focusing on implementation of these interventions and 
their effectiveness on improving the infant health outcomes are necessary. 
 Second, future research could benefit by addressing the limitations of our study. 
We were not able to link maternal health information to infant data. Maternal health 
information could be key in further explaining post-discharge health care utilization. 
Furthermore, a greater focus on the future impact of the exposure to opioids within the 
context of NOWS management, is merited. Our study could not explore dose-response 
relationship of opioids in relation to post-discharge healthcare utilization. Detailed 
examination of these treatments could reveal unexplained variations in the outcomes of our 
study (or infants born with NOWS).  
Our study did not specifically evaluate the reasons for post-discharge healthcare 
utilization. Little is known about the reasons what specific events or conditions results in 
emergency visits or rehospitalization. Examining the causes of these health care utilization 
events could help guide policy in creating policies to minimize unnecessary hospital 
readmissions and/or emergency room visits. There would also be additional benefit of 
following up these infants for a longer period of time to examine their health outcomes in 
adulthood. Other avenues of research include study of long-term economic impact of 
increased post-discharge health care utilization. Additionally, cost-effectiveness analysis 
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of difference measures of NOWS management (e.g. ESC or institution specific methods of 
care) would help facilitate adoption of these measures.  
Understanding how NOWS affects an infant holds the key to promoting policies 
and interventions that can improve health outcomes. We believe that this study provides a 
greater understanding of the long-term effects of NOWS. We hope this study serves as a 
guide for future research in improving the lives of infants diagnosed with NOWS at birth.  
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